NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics?

Abstract

In the setting of viral challenge, natural killer (NK) cells play an important role as an early immune responder against infection. During this response, significant changes in the NK cell population occur, particularly in terms of their frequency, location, and subtype prevalence. In this review, changes in the NK cell repertoire associated with several pathogenic viral infections are summarized, with a particular focus placed on changes that contribute to NK cell dysregulation in these settings. This dysregulation, in turn, can contribute to host pathology either by causing NK cells to be hyperresponsive or hyporesponsive. Hyperresponsive NK cells mediate significant host cell death and contribute to generating a hyperinflammatory environment. Hyporesponsive NK cell populations shift toward exhaustion and often fail to limit viral pathogenesis, possibly enabling viral persistence. Several emerging therapeutic approaches aimed at addressing NK cell dysregulation have arisen in the last three decades in the setting of cancer and may prove to hold promise in treating viral diseases. However, the application of such therapeutics to treat viral infections remains critically underexplored. This review briefly explores several therapeutic approaches, including the administration of TGF-β inhibitors, immune checkpoint inhibitors, adoptive NK cell therapies, CAR NK cells, and NK cell engagers among other therapeutics.

1 Introduction

Natural killer (NK) cells are a type of lymphocyte notable for their cytotoxic activity and role as an innate immune cell that acts as an early responder to physiologically stressed cancer and virally infected cells (1). NK cells are particularly important in viral infections, given their ability to respond to them before the development of adaptive immune responses (2). Evidence for a role of NK cells in the protection against certain viral infections is appreciated in patients with selective NK cells deficiencies; the hallmark clinical feature in these patients are severe and recurrent viral infections (3, 4). For example, of a group of 19 NK cell deficient patients, 42% died prematurely while 53% had experienced severe herpesvirus infections including cytomegalovirus, Epstein-Barr virus, Varicella Zoster virus, and herpes simplex virus (5). The dramatically increased incidence rate of severe complications related to these infections in patients with NK cell deficiency is strongly illustrative of their important role in combating and containing viral infections.

1.1 NK cell subsets

Like other immune cells, NK cells originate from CD34⁺ hematopoietic stem cells, and most of their development occurs in discrete stages. Commitment to the NK cell lineage relies on loss of CD3 and gain of the natural cytotoxicity receptors NKp44 and NKp46 (6). Roughly 5-15% of all circulating lymphocytes is made up of NK cells, and NK cells are known to also reside in secondary lymphoid tissue, bone marrow, lungs, liver, spleen, and uterine tissues.

NK cells have been divided into different populations based on the relative expression of surface markers CD56 and CD16 (FcgrIIIa), with the two largest subsets being CD56^bright and CD56^dim (7). CD56^bright NK cells constitute roughly 2-10% of all NK cells in the blood and are found mainly in the secondary lymphoid organs where they constitute 50% of the NK cells, whereas CD56^dim NK cells comprise 90% of NK cells in the blood (8). CD56^bright NK cells differentiate into CD56^dim NK cells and then express CD16 (9, 10). Functionally, CD56^bright NK cells are considered to be far less cytotoxic than their CD56^dim counterparts, and play a role in the production of antiviral proinflammatory cytokines like IFN-γ and TNF-α (7, 8). In contrast, CD56^dim NK cells are far more cytotoxic since they contain 10-fold more perforin and Granzyme B and due to their expression of CD16, which enables them to engage in antibody-dependent cellular cytotoxicity (ADCC) (11). CD16 is the only receptor known to activate NK cells on its own without activation through other receptors (12). Of note, CD56^dim NK cells are also capable of producing proinflammatory cytokines like IFN-γ, typically producing them two to four hours after stimulation, whereas CD56^bright NK cells predominantly produce cytokines 16 hours or more after stimulation (13). There is another subset of NK cells, termed adaptive (or memory-like) NK cells, that possess qualities of the adaptive immune system such as antigen-driven clonal expansion and long lived memory that have been recognized and will be examined in more detail later (14). Finally, there are also different subsets of NK cell populations that reside in peripheral tissues that carry distinct phenotypic markers (15).

1.2 NK cell receptors and signaling

NK cells are unique in their mechanism of recognition of dysregulated or infected cells. Instead of solely recognizing viral peptides presented by major histocompatibility (MHC) molecules like cytotoxic T lymphocytes, NK cell activation is dependent on the balance between different activating and inhibitory receptors to distinguish between virally infected and uninfected cells in a non-antigen-specific manner. Many NK cell receptors sense surface expression of MHC class I molecules as well as MHC class I chain related (MIC) molecules among others (16). NK cell activation will only occur if the activating signal overrides the inhibitory signal (Figure 1) (17). Importantly, NK cells can recognize virally infected cells or tumor targets without prior sensitization to antigens. Some viruses will down-regulate MHC-I to interfere with the presentation of viral antigens, thereby escaping cytotoxic T lymphocytes. This downregulation of MHC-I promotes the recognition and killing of virally infected cells by NK cells. This concept of recognizing cells that lack MHC-I is known as the “missing-self” hypothesis (18).

Figure 1

Activating receptors include natural cytotoxicity receptors (NCRs) such as NKp30, NKp44, NKp46, and NKp80, in addition to some receptors of the NKG2 family, including NKG2C, NKG2D, and NKG2E (7, 19). Resting NK cells can express NKp30, NKp46, and NKp80 whereas NKp44 is expressed by activated NK cells (20). The acquisition of natural cytotoxicity receptors during NK cell maturation is correlated with the development of cytotoxic activity against tumor cells depicting the receptor family’s importance in NK cell activation (21). NKG2C and NKG2E form heterodimers with CD94 which bind to HLA-E, an interaction that supports NK cell expansion in antiviral responses (17). Another activating receptor is DNAM-1 which binds nectin and nectin-like molecules (22).

Inhibitory receptors include the members of the killer cell immunoglobulin-like (KIR) receptor family that have long cytoplasmic tails (23). Of note, while many KIR receptors are inhibitory, a portion are activating and have short tails, and some can be both activating and inhibitory (24). Similarly 2B4 is another NK cell receptor that has been observed to be both activating and inhibitory depending on the presence of modulating co-receptors and signaling molecules (25). NKG2A/CD94 heterodimers also serve as another important inhibitory receptor that binds HLA-E as its ligand (26). In the blood, approximately 50% of NK cells express NKG2A/CD94 receptors (27). In terms of NK cell differentiation, it has been noted that the NK cell maturation process entails a stepwise decline in NKG2A with a simultaneous increase in killer immunoglobulin-like receptors (KIRs) (28). TIGIT, LAG-3, TIM-3, and PD-1 receptors are classically defined as inhibitory receptors on cytotoxic T lymphocytes, but can serve a role in modulating NK cell responses in an inhibitory or activating fashion depending on the context (29, 30).

1.3 Genetic variation in NK cell receptors and ligands

Adding to the complexity of NK cell signaling, extensive genetic diversity exists within many NK cell receptors and ligands, particularly within the KIR receptor family and HLA genes (31–33). To elaborate, the KIR receptor family has been found to vary widely in terms of the presence of different KIR genes, copy number of KIR genes, and there exsists substantial polymorphism within these genes resulting in markedly different KIR repertoires between individuals (34, 35). Two primary haplotypes have been identified and termed group A and group B (36). The group A haplotype is relatively consistent in its makeup, consisting of the activating KIR receptor KIR2DS4 and the inhibitory KIR receptors KIR2DL1, KIR2DL3, KIR3DL1, KIR3DL2, and KIR2DL4 (31). In comparison, the B haplotype is less fixed and contains one or more activating KIR receptor along with genes encoding the inhibitory KIR receptors KIR2DL5A, KIR2DL5B, and KIR2DL2. Within haplotypes, group A varies in terms of allelic polymorphisms in its constituent genes, while group B varies more in terms of gene content and copy number, although allelic variation is also a consideration too (36). The HLA gene family, whose constituents serve as ligands for many NK cell receptors encompasses more than 35,000 different MHC alleles, making it the most polymorphic region in the human genome (37). The implications of this diversity on NK cell signaling are made very apparent by the observation that various combinations of KIR receptors and HLA ligand have displayed differential functional activation (32, 38–40), and have additionally been associated with infection outcome in human immunodeficiency virus (HIV) (41, 42), hepatitis C virus (HCV) (43), SARS-CoV-2 (44), and ebola virus (45).

A similar effect can be observed from the effect of genetic variation within the NKG2D/NKG2DL signaling axis. While NKG2D is evolutionarily conserved relative to the KIR receptor family, distinct haplotypes exist and have been implicated in predisposing different cancer risk (46), as well as being a prognostic factor for treatment free remission in the setting of chronic myeloid leukemia (47). In humans, the ligands for NKG2D are MIC and ULBP which are upregulated by virally infected cells, and both of these ligands display extensive polymorphism (48). Certain alleles in these ligands have been associated with diseases like Dengue shock syndrome (49, 50), colorectal cancer (51), oral squamous cell carcinoma (52, 53), breast cancer (54), and cervical cancer (55). Taking the examples of the KIR receptor family and NKG2D/NKG2DL axis together, it is very evident that the genetic content of an individual's NK cell repertoire plays a significant role in the regulation of NK cell function in disease.

1.4 Additional NK cell markers

Other notable NK cell markers include CD57, CD69, and CD107a. CD57 expressing NK cells are connected with terminal differentiation, senescence, and high cytotoxic potential (56). CD69 is a marker expressed by NK cells during acute activation (57, 58). Additionally, CD69 has been shown as a marker of tissue resident NK cells (59). CD107a is expressed on the inner membrane of cytotoxic granules containing molecules like granzymes and perforin, which are released upon NK cell activation. When the granule is released, its membrane fuses with the outer cell membrane making cells that released granules positive for CD107a. Therefore, CD107a as a marker is indicative of NK cell granule release (degranulation) (60).

NK cells primarily kill infected cells through the release of granules containing granzyme-B and perforin, a serine protease that activates apoptosis and a protein that forms pores in the membrane of targeted cells, respectively (61, 62). In this process, perforin enables granzymes to infiltrate past the membrane of target cells, where they cleave internal components including procaspases that then initiate apoptosis (63). ADCC is another important mechanism through which NK cells kill target cells. In ADCC, the target cell is bound by antibodies and the Fc region of these antibodies in turn binds CD16, ultimately triggering the release of cytotoxic effector molecules that kill the target cell as described above (64).

During the NK cell response to viral infection, the repertoire of NK cell activating and inhibitory receptors is altered, often with an impact on the functionality of these cells. The aim of this review is to summarize these changes, particularly those related to NK cell dysregulation and exhaustion in the context of HIV, HCV, influenza A viruses (IVA), cytomegalovirus (CMV), and SARS-CoV-2. These viruses were chosen due to their clinical relevance and the existence of a plethora of literature noting alterations in NK cell phenotype and repertoire during their pathogenesis. Each of these viruses represent different viral families, and furthermore, the selection offers perspective into the similarities and differences between acute and chronic viral infections’ impact on the NK cell population. Further, potential therapeutics that could help maintain, or enhance an effective NK cell response will be explored.

2 NK cells during viral infection

2.1 Human Immunodeficiency Virus (HIV)

HIV belongs to the Retroviridae family and has a genome that consists of two single-stranded RNA molecules (65). HIV primarily targets CD4⁺ T cells and ultimately results in their depletion rendering those infected progressively immunocompromised and susceptible to opportunistic infections and rare forms of cancer (66). With contemporary antiretroviral therapy (ART), replication of the virus can be controlled to the extent that patients on ART are aviremic (66). However, ART is not curative due to the establishment of reservoirs of infected cells that persist in lymphoid tissue and are often latent (67). Significant attention has been placed on characterizing the role of NK cells in HIV infection within both the blood and lymphoid tissue given the nature of the infection.

In the context of HIV infection, and the general immune dysregulation incurred by depletion of CD4 T cells, NK cells undergo significant changes regarding their receptor expression and functional activity. HIV progression in terms of declining CD4 T cell counts is associated with a decline in the quantity of cytotoxic CD56^dim NK cells (68, 69). The remaining CD56^dim NK cell population has CD57 and KIR receptor expression characteristic of a more mature phenotype. However, these cells have decreased functional potential evidenced by their lower degranulation ability and perforin expression (70, 71). Regarding the CD56^bright NK cell population, they express CCR7, a chemokine receptor associated with tissue trafficking; this has been noted to decrease. This decrease in CCR7 expression has been correlated with HIV viral load (72), supporting the idea that issues in NK cell trafficking contributes to a failure to contain HIV replication. Moreover, CD56^bright NK cells have also been found to be more expressive of TGF-β during HIV infection, which is of note as TGF-β inhibits immune effector functions (73, 74). As HIV infection progresses, an expansion in the amount of CD56^neg NK cells has also been observed (Figure 2) (71, 75, 76). In healthy subjects, the CD56^neg NK cell subset constitutes roughly 5.7% of NK cells in the peripheral blood, which has been shown in a meta-analysis to increase by an average of 10.6% after HIV-1 infection (77). CD56^neg NK cells have significantly impaired cytotoxic function due to expression of a relatively high quantity of inhibitory receptors (78). Furthermore, this cell population is known to produce a greater quantity of TGF-β, a cytokine associated with anti-inflammatory and homeostatic functions. TGF-β may also hinder autologous CD8 T cell functionality and potential to generate IFN-γ (79). The CD56^neg NK cell population is also known to expand in other chronic viral infections including hepatitis C virus (HCV), Epstein-Barr virus (EBV), and chronic cytomegalovirus (CMV). This observation suggests that it is likely a common feature among chronic viral infections (80).

Figure 2

During HIV infection, the expression of activating natural cytotoxicity receptors (NCRs) like NKp80 and NKp46 in NK cells are suppressed (81). Regarding inhibitory receptors, HIV viremia is associated with a significant increase in the expression of inhibitory KIR receptors, while NKG2A has been shown to decline, and taken together, the alterations in the expression of both activating and inhibitory receptors is associated with diminished cytolytic function (82). Additionally, the expression of CD69, CD18, and CD11b are also decreased, further suggesting functional impairment (83). A decrease in IFN-γ production by NK cells has also been observed, and coinfection with hepatitis C virus (HCV) is found to synergistically impair functional ability, with even further reduced IFN-γ and degranulation ability (84, 85).

To avoid targeting by cytotoxic T-lymphocytes, HIV selectively downregulates MHC-I molecules HLA-A and HLA-B, but largely retains HLA-E and HLA-C in some individuals in an attempt to avoid lysis by NK cells (86). This occurs in a mechanism dependent on HIV’s Nef protein and results in the aforementioned surface MHC-I molecules being rapidly internalized and degraded (87). Similarly, HLA-C has been shown to be downregulated by HIV-1’s viral protein U (Vpu) in some individuals, though not all (88, 89). HIV has been shown to induce the expression of ligands for NKG2D in infected cells by a mechanism dependent on its Vpr protein (90). The subsequent NK cell activation is speculated to contribute to CD4 T-cell depletion and NK cell dysfunction as sustained exposure to its ligand desensitizes the NKG2D receptor, resulting in its downregulation and diminished NK cell cytotoxic activity (91, 92). However, it is worth noting that NKG2D signaling alone is not enough to trigger NK cell degranulation as it requires coactivation with NK-T-B-antigen (NTB-A) which is downregulated through the action of Vpu enabling escape from the NK cell response (93). Also of note is that HLA-E is capable of displaying HIV antigen that blocks interactions with NKG2A limiting inhibitory NK cell signaling by this mechanism. This contrasts with HLA-C, which remains unblocked during HIV infection resulting in conserved inhibitory signaling via KIR receptors. This suggests that HIV⁺ cells are uniquely susceptible to NKG2A expressing NK cells that lack inhibitory KIR receptors (94), and therapeutics taking advantage of this possibility deserve further exploration. Similarly, the blocking of interactions between HLA-A and HLA-C with NK cell inhibitory receptors have enhanced cytotoxicity against HIV infected cells (95).

During early HIV infection, NK cell numbers and distribution remain relatively unaltered. KIR⁺ NK cells remain rare at this stage, and the relative naivety of the NK cell repertoire limits their ability to control the infection (96). As HIV infection progresses, there has been an observed increase in the number of CXCR5⁺ NK cells in lymphoid tissue (97). This population of NK cells highly express activating receptors, including NKG2D and NKp44, although they do demonstrate functional impairment, with reduced degranulation compared to CXCR5⁺ NK cells in non-infected individuals. Most notably, the frequency of these cells is negatively correlated with HIV-1 burden in the lymph tissue, illustrating their potential importance in controlling the HIV-1 reservoir.

Also found within lymph tissue is a subset of CD56^bright NK cells which express a high quantity of NKG2A inhibitory receptors, as well as NKG2D, NKp46, and NKp30 activating receptors (98). This subset is also relatively immature in regards to its differentiation status and cytotoxic potential due to expressing only low quantities of CD57 and CD16. In humanized MISTRG-6-15 mice, after HIV-1 infection, NK cells in the lymphoid tissue were relatively less mature and similarly more dysfunctional when compared to NK cells in the nonlymphoid tissues, consistent with this previous result (99). However, this observation may be in part driven by mismatched trafficking receptors impairing infiltration of NK cells into lymphoid tissue in this mouse model. Within the gut mucosa, two distinct subsets of NK cells located in the intraepithelial spaces and lamina propria are significantly diminished in prevalence during chronic HIV infection which contrasts with spontaneous HIV controllers who have a stable intraepithelial subset (100).

In terms of KIR receptor expression, the expression of the activating KIR2DS4 has been shown to decrease while the expression of other inhibitory KIRs remains constant with exception of KIR3DL2 which increases (101). Interestingly failure to downregulate KIR2DS4 has been associated with increased viral replication possibly due to promoting excessive NK cell activation in chronic HIV (102, 103). Similarly, the possession of inhibitory KIR receptor KIR2DL3 has been associated with increased chronic immune activation, especially when an individual is also a carrier of HLA-C2 (104). This same study also noted that carriers of activating KIR3DS1 also display heightened immune activation during chronic HIV. Further study has shown that KIR3DS1⁺ NK cells in the presence of the receptor’s cognate ligand display enhanced ability to control HIV infection in vitro and result in lower viral set points in vivo (105, 106). Overall, these studies again highlight the importance of an individual’s KIR and HLA repertoire, as the presence of certain receptor-ligand genes are associated with different functionality in HIV.

Mounting evidence also suggests that HIV infection is associated with an increase and persistence of memory NK cells (107). For example, macaques infected with either SIV or SHIV have been found to develop a subset of antigen specific NK cells present in the spleen and liver that specifically lyse dendritic cells pulsed with viral antigens like GAG or ENV (108). This mechanistically occurs in an NKG2C dependent manner and markedly contrasts with NK cells isolated from healthy macaques that lysed fewer cells in a non-specific manner. In humans, the presence of rare HIV peptide specific NK cells has been observed and is also associated with lower viral load, higher CD4 counts, and stronger HIV specific T-cell responses (109, 110). Further study is required to elucidate the mechanism by which these cells arise and to explore their function in greater detail. An expansion in NKG2C⁺ memory NK cells have also been described in early HIV infection and patients with high NKG2C⁺ CD57⁺ NK cell frequencies have been found to show lower immune activation and HIV RNA one month after starting antiretroviral therapy (ART) (111). The patients in this study were seropositive for cytomegalovirus (CMV), so from this data it is indeterminable the degree to which this memory NK cell population was induced by HIV infection itself. Regardless, further characterization of the functional role of NKG2C⁺ CD57⁺ memory NK cells in HIV is needed.

ART does not normalize the phenotypic changes observed in the CD56^dim, CD56^negative, and CD56^bright NK cell subsets caused by HIV infection (112). Deficiencies in the prevalence of CD56^dim and CD56^bright, as well as the expression of CD107a, Granzyme-B, NKG2D, and NKp46, remain following ART therapy suggesting prolonged NK cell functional impairment (113). In spite of functional impairment, NK cell activation persists following viral suppression by ART (114). However, the cytokine-induced expression of IFN-γ and activating receptor NKp44 are also reduced, and CD56^bright cell counts are inversely correlated to the decreased T regulatory cell counts observed during ART, suggesting autoreactivity (115). In contrast, the relative expression of inhibitory receptors after ART does appear to return and is comparable to healthy donors (82). Despite ART, the dysregulation of NK cells in HIV is a clear component of the infection’s immunopathogenesis and is an avenue that many of the therapeutics discussed later are targeting for cure strategies.

2.2 Hepatitis C Virus (HCV)

Hepatitis C Virus (HCV) belongs to the Flaviviridae family and has a single-stranded RNA-genome (116). HCV primarily infects hepatocytes, but can also replicate in macrophages, B cells, and T cells, among other extrahepatic tissues (117). While HCV infection is often asymptomatic, chronic infection is frequently associated with the development of liver fibrosis and in severe cases cirrhosis (118).

In regards to the NK cell response, the relative prevalence of CD56^bright NK cells increases, while the prevalence of CD56^dim NK cells slightly decreases in the blood during acute HCV infection (119). Additionally, both subsets have been found to upregulate the expression of activating receptor NKG2D while demonstrating strong cytokine production and cytotoxic activity. Following acute infection, approximately 25% of individuals spontaneously clear the virus, though the virus persists in the majority of individuals leading to chronic infection (120). Self-clearing HCV infections have been associated with highly differentiated NK cell phenotypes with increased expression of CD57 and KIR receptors (KIR2D, KIR3DL1, and KIR3DL2) and decreased expression of NKG2A (Figure 3) (121). Furthermore, certain NK cell phenotypes, like the expression of NKp30, are associated with spontaneous clearance (122). Homozygosity in KIR2DL3 and HLA-C1 has also been strongly associated with spontaneous clearance (43). The expression of inhibitory receptors NKG2A and inhibitory KIR2DL3 has been found to increase during chronic HCV infection while the expression of NKp30 and NKp46 was decreased relative to healthy controls (123, 124). Additionally, possession of HLA-B*44, HLA-C*12, and KIR3DS1 have been associated with failure to spontaneously clear HCV (125). Overall, the correlation of self clearance with the presence of mature, functionally active NK cells, as well as the presence or absence of specific KIR receptors suggests NK cell involvement in determining the chronicity of HCV.

Figure 3

Chronic HCV infection has also been associated with a significant decline in the total number of NK cells, specifically the CD56^dim subset in the peripheral blood (126, 127), similar to what occurs during chronic HIV infection. Additionally, the relative proportion of CD56^bright NK cells in the blood appears to increase during chronic infection due to both expansion of the subset, and the decline of CD56^dim NK cells in the blood (128, 129). For example, the CD56^dim NK cell subset has been observed to shrink to 4.9% of total lymphocytes in the blood during chronic HCV infection from 9.0% in healthy controls (123). In an ex vivo study, extracellular HCV-core protein was found to be correlated with the frequency of CD56^bright NK cells, suggesting that the protein attenuates NK cell differentiation and may help explain the increased prevalence of more naive CD56^bright NK cells (130). This direct viral modulation, along with other explanations providing rationale for the changes in NK cell subset prevalence in the blood during chronic HCV infection like tissue homing, would benefit from further investigation.

NK cells in the liver are predominantly of the CD56^bright subset, and liver fibrosis is associated with the diminished expression of activating receptors, including NKG2D and NKp46 (131). During chronic HCV infection, IL-26, has been found to be overexpressed (132). IL-26 is a cytokine that was recently identified as an inflammatory mediator, which binds extracellular DNA from damaged cells and induces activation of myeloid and lymphoid cells (133). The overexpression of IL-26 during HCV in turn upregulates TNF-related apoptosis-inducing ligand (TRAIL) expression on CD56^bright NK cells, increasing their ability to kill HCV-infected hepatoma cells (132). Additionally, an increase in the number of intrahepatic NKp44⁺ NK cells has been observed during chronic HCV (134). These intrahepatic NKp44⁺ NK cells are potent producers of TNF-α, and their frequency has been positively correlated with both HCV-RNA and fibrosis stage, indicating they may play a role in liver damage. It has also been observed that the relative prevalence of resident liver NK cells relative to circulating NK cells increases in the setting of cirrhosis, further suggesting NK cell involvement in HCV related liver fibrosis (135). Further work exploring if the NK cell response in the liver is mediating liver fibrosis or attempting to inhibit it through IL-10 and other mechanisms is needed to better understand the pathogenesis.

Functionally speaking, NK cells from HCV infected patients have a reduced capability to degranulate and produce cytokines (136). As infection progresses, reduced expression of NKG2D, NKp30, NKp46, and an increase in the CD56^neg NK cell subset and NKG2A expression is observed (137). Remaining CD56^dim NK cells also express CD16 to a lesser degree, limiting their ADCC ability (128). Additionally, hepatocytes in humanized mice upregulate Qa-1 (a murine functional homolog to HLA-E), which significantly contributes to NK cell exhaustion through inhibitory NKG2A receptor signaling (138). Furthermore, anti-NKG2A antibodies have been shown to restore NK cell production of IFN-γ in mice, resulting in decreased viral replication, demonstrating the relative importance of this pathway in NK cell exhaustion. Such immune checkpoint inhibitors will be explored further later.

Direct acting antiviral (DAA) therapy has been shown to normalize many of the changes in the NK cell repertoire associated with chronic HCV infection. For example, the prevalence of CD56^dim NK cells increases and the prevalence of the CD56^bright NK cell subset decreases, reverting both to levels comparable to healthy controls (139, 140). DAA has also been associated with decreased NK cell activation in the periphery, as well as decreased IL-12, IL-18, NKp30, NKp46, and TRAIL expression (139, 141). This further supports the idea that DAA, and by extension the decline in viral titers it causes results in diminished NK cell activation, and also teases NK cell involvement in the mediation of liver damage, due to treatment resulting in declining NK cell activation.

2.3 Cytomegalovirus (CMV)

Cytomegalovirus (CMV) is a member of the Herpesviridae family and has a large linear double-stranded genome (142). The virus infects a wide assortment of cells including epithelial cells, fibroblasts, monocytes, and macrophages and establishes a latent reservoir that is prone to later reactivation (143). The most notable feature of NK cells in CMV infection is the expansion of NKG2C⁺ CD57⁺ memory NK cells, also known as adaptive NK cells (144–147). These cells are phenotypically mature CD56^dim NK cells that express NKG2C, and persist after acute infection (148). Further, this NKG2C NK cell population preferentially expresses the inhibitory KIR2DL receptors, which has been described as contributing to increased functionality (149). CMV seropositivity is also associated with a decline in the expression of NKp30 and an increase in NKp46 (Figure 4) (150).

Figure 4

A similar expansion of NKG2C⁺ CD56^dim NK cells has been observed during CMV coinfection with viral hepatitis (both hepatitis B and C), suggesting that CMV-related NKG2C expansion is prominent even in the setting of other viral infections (151). This NKG2C⁺ memory NK cell population has been found to be have a greater capacity for ADCC and a potent capability to produce TNF-α and IFN-γ (152). As described earlier, these NKG2C⁺ CD57⁺ NK cells have been coined adaptive NK cells due to their selective proliferation, persistence, and functional potency in the setting of CMV infection, comparable to that of the adaptive immune system (153). The emergence and persistence of NKG2C⁺ CD57⁺ NK cells secondary to CMV infection are thought to be driven by epigenetic changes (154, 155).

Hematopoietic stem cell transplant (HSCT) recipients who experienced CMV reactivation post-transplant show a similar increase in the proportion of adaptive NK cells (156). These adaptive NK cells persist in the body for at least a year in post-HSCT recipients (157). In contrast, CMV seronegative recipients retain a population of comparatively less mature NK cells, presumably offering these recipients less protection. This is especially important considering that NK cells are among the first lymphocytes to recover status post-HSCT (158). This expansion of NK cells associated with CMV reactivation is also linked to a significant increase in the number of all NK cell subsets that persists even without further viral reactivation (157). Furthermore, NKG2C⁺ NK cells transplanted from CMV seropositive donors display heightened function during CMV reactivation (159). This supports the idea that NKG2C⁺ memory NK cells are also potentially transplantable and have rationale as a therapeutic which deserves further exploration.

2.4 Influenza Virus A (IVA)

Influenza A Viruses are members of the Orthomyxoviridae family and have a segmented genome consisting of 8 linear RNA strands (160). They are further subtyped based on the hemagglutinin (HA) and neuraminidase (NA) they express, which are surface glycoproteins that help mediate viral entry and exit respectively (161). Influenza viruses primarily infect epithelial cells of the upper and lower respiratory tract, and severe cases can result in acute respiratory distress syndrome (162).

Influenza virus A (IVA) infection induces the infiltration of NK cells into lung tissue with a significant increase in the number of NK cells expressing CXCR3, CXCR6, and CCR5, all of which are markers of tissue homing (163, 164). In mice, this infiltration is also in part regulated by IL-15 as evidenced by the blocking of IL-15 delaying this infiltration (165). Severe infection is associated with a decline in the total number of NK cells in the peripheral blood, particularly among CD56^bright NK cells, along with marked NK cell activation evidenced by an increase in the proportion of NK cells expressing CD69 (166, 167).

As a whole, there is a decrease in the number of NK cells expressing NKp46 but an increase in the number of cells expressing coreceptor 2B4 in the blood and these cells also show a greater degree of activation (168). Of the remaining NKp46 expressing NK cells, the proportion of NKp46⁺ NKp44⁺ NK cells expands while the proportion of NKp46⁺ NKp44^- declines, contributing to the shift towards NK cell activation (169). An NKp46⁺ NKG2A⁺ NK cell subset has also been found to be induced by IVA infection. This subset of NK cells has demonstrated a memory phenotype in that upon reencountering previously exposed influenza antigen, they display decreased cytotoxicity and increased IFN-γ production (170). Influenza is also directly capable of infecting NK cells, triggering apoptosis, and infection has been shown to inhibit NK cell cytotoxic function (171–173).

In the lung, tissue resident NK cells comprise 10-25% of the NK cell population meaning that most NK cells in the lung are circulating NK cells (15). The majority of lung tissue resident NK cells are CD16^- and have similarly been divided into CD56^dim and CD56^bright subsets in some studies (15). Functionally, the CD56^bright lung tissue resident NK cells subset has been described as showing greater functionality, with increased degranulation and IFN-γ production in response to IVA infection compared to other NK cells ex vivo (174). The rationale behind this subsets enhanced function is poorly understood and whether or not it translates in vivo is unknown.

Differential activation of NK cells has been observed following coculture with replication deficient influenza A pseudotypes that express IVA HA and NA (175). Particularly, more robust upregulation of CD69, CD107a, and IFN-γ along with downregulation of NKp46 is observed with H5N1, and the 1918 H1N1 compared to 2009 H1N1 (Figure 5) (175). More broadly speaking, Influenza induces both degranulation and cytokine production, particularly in CD56^bright NK cells, and while their activation contributes to host immunity, it may well contribute to tissue damage as well (176). For example, NK cell-depleted mice infected with a high dose of influenza A virus have decreased mortality and disease morbidity illustrating how the NK cell response can be deleterious (177). Conversely, a study looking at NK cell responses in chickens challenged by either a weakly pathogenic H9N2 avian influenza virus or a highly pathogenic H5N1 avian influenza virus found that the less pathogenic avian virus induced a more vigorously activated NK cell response (178). This shows that a notable NK cell response in influenza is not always associated with viral virulence and may even be protective. Additionally, CD94 expression has been negatively correlated with influenza symptom severity, suggesting that signaling through CD94 containing receptors plays a role in control of IVA infection (179). Overall, more work is required to characterize differential NK cell responses between influenza viruses, and what correlates are predictive of deleterious responses.

Figure 5

The IFN-γ response orchestrated by NK cells is particularly important in the context of infection. Notably, impairment of NK cell activation and IFN-γ secretion is associated with weakened cytotoxic T lymphocyte activity against influenza (180). This has been corroborated in mice, and the initial increase in production of IFN-γ after NK cell activation results in downstream cytotoxic function in CD8 and NK cells during influenza infection (181). This potent IFN-γ response orchestrated by NK cells has also been implicated in contributing to thymic atrophy during influenza A infection, showing it can also be deleterious (182).

Influenza vaccination has also been shown to prime NK cell function with patients displaying increased production of IFN-γ and enhanced activation after stimulation, while NK cell phenotype and subset is largely unaltered (183, 184). However, influenza vaccination does induce a proportion of CD56^dim NK cells to become memory NK cells and express intracellular NKp46, offering a possible mechanism by which the IFN-γ NK cell response is enhanced after vaccination (185). These vaccine induced memory NK cells display a heightened IFN-γ response that persists 6 months after vaccination. It has also been found that NK cells in mice vaccinated with a multivalent influenza vaccine had greater expression of granzyme B and perforin and took on a more mature phenotype after being challenged by heterosubtypic influenza strains compared to unvaccinated mice (186). This again supports the notion that influenza vaccination primes NK cells to offer greater protection even against heterosubtypic strains where vaccine-derived humoral immunity may struggle. Changes in the NK cell population induced by other vaccines remain underexplored, and examining these NK cell phenotypic changes induced by vaccines as a correlate of immunity warrants more attention.

2.5 SARS-CoV-2

SARS-CoV-2 belongs to the Coronaviridae family and has a large single-stranded RNA genome (187). The virus primarily infects ACE2⁺ cells of the respiratory tract, particularly type II alveolar pneumocytes and in severe cases can result in acute respiratory distress syndrome (188). Severe COVID-19 disease has been linked to a significant decline in CD56⁺ CD16⁺ NK cells in the blood (189–191). This decrease in circulating NK cells is correlated with acute SARS-CoV-2 infection and is associated with disease severity (192, 193). In hospitalized patients, NK cell counts correlate directly with the speed of viral load decline. For example, those with normal NK cell numbers in the blood showed a faster decline of viral load compared to those with low NK cell numbers, suggesting that circulating NK cells may represent a prognostic clinical marker of COVID-19 severity and outcome in adult patients (194). When patients recover after COVID-19, their circulating NK cell counts return to normal. In patients affected by long COVID-19, NK cell counts have recovered, despite continued symptoms (195). In Multisystem Inflammatory Syndrome in Children (MIS-C), a severe post-infectious complication that occurs 4-6 weeks after COVID-19 infection, CD56^dim NK cells are also decreased in number (196).

During COVID-19, NK cells are robustly activated, evidenced by an increase in the expression of CD69, and KI-67 a proliferation marker (192). Expression of the genes KLRD1 and KLRG1, which encode CD94 and killer cell lectin-like receptor G1 respectively, are also noted to decrease in many patients contributing towards NK cell activation (197).

SARS-CoV-2 infection has also been linked to an increase in the expression of NKG2C, creating a population similar to the earlier described memory NK cells (192, 198). Interestingly in patients with adaptive NK cells, there was no detectable circulating CMV DNA, suggesting that the expansion of adaptive NK cells in severe COVID-19 patients may be independent of CMV reactivation secondary to COVID-19. It is still to be determined if SARS-CoV-2 itself can drive the expansion of adaptive NK cells or if they are driven by the production of pro-inflammatory cytokines. In those affected by long COVID-19, there are increased levels of CD57⁺ NKG2C⁺ memory NK cells; these are one of the variables important for predicting a higher susceptibility to develop long COVID-19. However, despite greater populations of memory-like NK cells, their effector functions remained impaired (195).

The expression of cytotoxic effector molecules like perforin and Granzyme A are also significantly increased during most COVID-19 cases (189, 199, 200). While these cytotoxic effectors are upregulated, NK cells from COVID-19 patients have been shown to have reduced degranulation potential and cytotoxicity (201). Furthermore, in severe cases, the quantity of TNF-α and IFN-γ produced by NK cells is diminished (202–204). Inhibitory KIR and NKG2A receptors have been found to be upregulated during COVID-19 and likely contribute to NK cell exhaustion (205, 206) NKG2A is also highly upregulated in acute, severe COVID-19 patients, while mild and moderate patients show a recovery of NKG2A after resolution of the infection (198). Significant NK cell exhaustion is further supported by the increased frequency of programmed cell death protein 1 (PD-1), Lymphocyte-Activation Gene 3 (LAG-3), and TIGIT, as well as a decreased frequency of NKG2D. However, the level of PD-1 expression in NK cells isn’t correlated with disease severity (203, 204), while decreased expression of TIGIT and DNAM-1 have been associated with slower viral clearance (207). Overall, more work is needed to ascertain the degree to which exhaustion is responsible for NK cell’s diminished function in COVID-19, as opposed to issues in tissue homing.

Infection has also been linked to the expansion of the CD56^dim CD16^neg NK cell population, which has decreased cytotoxic potential compared to the standard CD56^dim CD16⁺ NK cell subtype (Figure 6). It has also been shown that CD56^dim CD16^neg NK cells expand in the early phases of SARS-CoV-2 and then decrease in mild or moderate cases, but in severe COVID-19 cases, this subset continues to expand (208). The study also suggests that loss of CD16 is potentially being mediated by cleavage through Adam17 in these cells (208). In MIS-C, studies have shown that there is a decrease in the prevalence of CD16⁺ NK cells, suggesting that there is a decrease in NK cell ADCC function in MIS-C (200). However, further studies are needed to explore NK cell function in MIS-C directly beyond just immunophenotyping.

Figure 6

In fatal COVID-19 cases, patients had impaired upregulation of perforin, granzyme-A, and KI-67, suggesting that defects in NK cell cytotoxic activity are associated with increased morbidity and mortality (209). Corroborating this is the observation that NK cell mediated ADCC appears to be impaired in severe COVID-19 (210). In the context of COVID-19 infection, TGF-β signaling has been associated with a stark reduction in NK cell effector functions, with patient serum having been found to inhibit NK cell cytotoxicity in a TGF-β dependent manner (194). Similarly, impairments in IFN-γ production appear to occur in a TGF-β dependent manner (211). This suggests that TGF-β signaling contributes significantly to NK cell dysregulation and exhaustion during COVID-19.

3 NK cell therapeutics

Given the extensive changes in NK cell phenotype and repertoire, which often lead to exhaustion and dysregulated NK responses in viral infections, several therapeutic approaches with the goal of promoting NK cell function are under investigation. The majority of NK cell-related therapies originate from the domain of cancer biology and have only recently been studied in the context of viral diseases.

3.1 TGF-β inhibitors

The development of therapeutic TGF-β inhibitors largely stems from the implication of aberrant TGF-β signaling in the pathogenesis of cancer, cardiovascular disease, and fibrosis. As a therapeutic class, they span a wide variety of structures from small effector drugs to blocking antibodies targeting a diverse host of TGF-β pathway components (212, 213). TGF-β signaling in HIV infection has been documented to promote latency by upregulating the transcriptional repressor Blimp-1 (214, 215). Galunisertib, a TGF-β type I receptor inhibitor, was administered to SIV infected rhesus macaques, where it was shown to increase reactivation of the SIV latent reservoir, and enhance the subsequent immune response to SIV (216). TGF-β signaling during SARS-CoV-2 infection has also been associated with NK cell dysregulation that limits functional activity contributing to subsequent viral pathogenesis (194, 217), showing that TGF-β inhibitors may have rationale to be applied in acute viral infections too.

Broadly speaking, TGF-β signaling has been shown to impair NK cell cytotoxic function in part by restricting the IL-15 activation of the mTOR pathway (218). Additionally, deletion of the TGF-β receptor subunit TGF-βRII has been shown to promote the cytotoxic function of NK cells in response to IL-15, enhancing the ability of NK cells to limit metastasis in two different murine tumor models (218). It is worth noting that by inhibiting NK cell cytotoxic function and the secretion of proinflammatory cytokines like IFN-γ, TGF-β plays an important role in limiting excessive NK cell activation. The risk of NK cell hyperresponsiveness, and the subsequent inflammatory environment and tissue damage this induces, should be considered in the testing of TGF-β Inhibitors. However, considering the clear contribution of TGF-β signaling to NK cell dysregulation and evidence that restraining this signaling may actually promote NK cell cytotoxicity beneficially, there warrants further investigation into the use of TGF-β inhibitors as a potential therapeutic for treating viral infections.

3.2 Immune checkpoint inhibitors

A key component of NK cell dysregulation is exhaustion driven by inhibitory pathways. These inhibitory pathways have been termed immune checkpoints, and immune checkpoint inhibitors have been developed to interfere with these pathways in an effort to preserve immune function (219).

NKG2A is an important inhibitory receptor expressed on most NK cells and is considered an immune checkpoint for NK cells. NKG2A inhibitors like the monoclonal antibody monalizumab have been found to promote antitumor immunity in treating squamous cell carcinoma by enhancing the activity of NK and CD8 cells (220). Monalizumab has also demonstrated a similar response in the setting of murine colorectal cancer (221), and against HLA-E⁺ leukemia and lymphoma in mice (222). NKG2A blocking monoclonal antibodies have also shown promise in treating viral hepatitis, with cultured NK cells from patient’s demonstrating enhanced cytotoxicity (223). Similarly, NKG2A-blocking monoclonal antibodies have been shown to restore the production of IFN-γ by NK cells during HCV infection, and has been associated with diminished CD8 T cell exhaustion (138). This therapeutic also has rationale to be applied in treating COVID-19 due to NK and CD8 T cell exhaustion being driven in part by increased NKG2A expression (205, 224, 225).

Antibodies targeting inhibitory KIR receptors have also emerged as another NK cell related immune checkpoint therapy. One such KIR inhibitor named IPH2101 which targets inhibitory KIRs (KIR2DL-1, KIR2DL-2, and KIRT2Dl-3) recently underwent a phase 1 study where it was deemed safe and tolerable and in ex vivo assays demonstrated increased NK cell cytotoxicity against multiple myeloma (226). However, a phase 2 study of IPH2101 was terminated due to lack of clinical efficacy (227), and similarly, a trial for lirulumab, another anti-KIR antibody (which targets KIR2DL-1, KIR2DL-2, and KIRT2Dl-3) was terminated for failing to meet objective response criteria (228). IPH2101 has also be combined with the anti-tumor drug lenalidomide in further testing against multiple myeloma with early data suggesting a promising synergistic effect, although more study is required (229, 230). As this study highlighted, a key advantage of immune checkpoint inhibitors is that they can readily be combined with other therapeutics. IPH2101 has also been tested in the setting of acute myeloid leukemia, where a degree of early TNF-α and CD69 upregulation was detected (231). Another anti-KIR antibody named IPH4102, targeting KIR3DL2, has also been tested in relapsed and refractory cutaneous T-cell lymphoma, which showed its potential to elicit a promising clinical response in 36.4% of the study participants (232). Little testing of KIR inhibitors has been undertaken in the setting of viral infections, although they warrant study particularly in HIV due to HIV viremia being associated with an increase in the expression of inhibitory KIR receptors (82).

PD-1 signaling has been implicated as a hallmark of T-cell exhaustion and a contributing factor of immune escape in the setting of cancer, and is considered another important immune checkpoint (233, 234). PD-1 signaling has been shown to be of significance to NK cells in multiple myeloma (235), renal cell carcinoma (236), and in Kaposi sarcoma (237), where it contributes to an exhausted NK cell response (29). Several PD-1 checkpoint inhibitors have been approved by the FDA including pembrolizumab, nivolumab, and cemiplimab among many others, which together have been tested clinically in a diverse arrangement of cancers (238). Significant expression of PD-1 has been shown in chronic HIV (239), HCB (240), HCV (241), Influenza (242), and SARS-CoV-2 (243), with a similar exhaustive effect.

In a mice influenza challenge model, PD-1 inhibitors were shown to enhance CD8 T-cell function resulting in quicker viral clearance (244). In SIV infected rhesus macaques, the blockade of PD-1 was well tolerated and resulted in the expansion of functional SIV-specific CD8 T-cells in the blood and gut as well as the expansion of memory B-cells all of which was associated with lower viral load and prolonged survival (245). Similarly, in CD4⁺ humanized mice, PD-1 blockade was associated with lower HIV viral load and increased T-cell counts (246). In HBV, PD-1 blockade has also been shown to again promote CD8⁺ T-cell expansion and secretion of IFN-γ and IL-2 (247). Importantly, the upregulation of PD-1 in NK cells during acute febrile malaria has been associated with enhanced ADCC, but otherwise diminished degranulation (248). This finding hints that the impact of PD-1 blockade on NK cells, may be more nuanced in terms of impact on functional activity than CD8 T cell function. Overall, more work is needed to characterize the impact that PD-1 blockade has on the NK cell population in the setting of these viral infections; however it is clear based on the CD8 T-cell response alone that PD-1 blockade is a promising therapeutic that deserves further examination in the setting of infectious diseases (249).

3.3 Adoptive NK cell therapies

Another therapeutic approach entails the administration of exogenous NK cells. The goal is to supply functionally intact cells to supplement NK cell functional activity during virally mediated NK cell dysfunction and exhaustion. The administration of allogenic NK cells has been safely and effectively used to treat leukemia (250). Delivery of exogenous NK cells have also demonstrated clinical responses in treating non-small cell lung cancer (251), platinum-resistant ovarian cancer (252), melanoma (253), and renal cell carcinoma (253). Very little work has been done studying adoptive NK cell therapies in infectious diseases. In SARS-CoV-2 and HIV-1, an additional consideration is the infusion of adaptive NK cells due to their enhanced cytotoxicity and persistence (198).

Recently, genetically engineered NK cell lines derived from induced pluripotent stem cells (iPSC) have emerged. Some of the gene edits in these cells include a non-cleavable CD16a receptor, a membrane-bound IL-15/IL-15R fusion protein, and knockout of coenzyme CD38 to promote the persistence and function of these cells after administration (254). In the setting of HIV, allogenic NK cells derived from human embryonic stem cells have been shown to decrease HIV replication during acute infection in humanized mice, and when combined with latency reversal, helped diminish the HIV reservoir (255, 256). Furthermore, phase 1 safety trials where haploidentical NK cells are infused into HIV infected ART suppressed patients in combination with either IL-2 or N-803 (an IL-15 superagonist) supportive therapy have been completed (NCT03346499, NCT03899480).

There are clinical trials using primary and iPSC-derived or “off-the-shelf” NK cells as therapeutics against SARS-CoV-2, suggesting that adoptive NK cells transfer may be a viable therapeutic in the setting of acute viral infection. An example of this is a phase 1 study in which a line of IPSC derived NK cells called FT516 administered to hypoxic COVID-19 patients to assess their safety and maximum tolerated dose. Results of this study (NCT04363346) are anticipated soon. Taken together, the demonstrated safety of utilizing exogenous NK cells, along with preliminary findings suggesting possible efficacy in treating viral infections, particularly in HIV, calls for further investigation.

3.4 Cytokine stimulation and cytokine induced memory like NK cells

Approaches to enhance NK cell anti-viral functions in vivo and prior to adoptive transfer of exogenous NK cells are of interest. In oncology, many cytokines have been used for the treatment of NK cell dysfunction, such as IL-12, IL-15, and IL-18 given their ability to promote NK cell expansion and maturation (257–259). In the context of SARS-CoV-2, a phase 2 clinical trial has been completed looking at the efficacy of low-dose IL-2 in acute respiratory distress syndrome (ARDS) related to COVID-19 (NCT04357444). NK cells treated with IL-15 and stimulated with an inactivated whole influenza virus were shown to mount a more vigorous NK cell response compared to when not treated with IL-15 (260). In HIV, NK cells stimulated with IL-15 demonstrated uniformly improved effector functions and the ability to kill HIV-infected cells that were treated with a latency reversal drug (261).

IL-12, IL-15 IL-18 are also of particular interest given their ability to induce changes in NK cells through transcriptional, epigenetic, and metabolic mechanisms that ultimately increase their cytotoxicity and result in memory like behavior (262). Cytokine induced memory like (CIML) NK cells have displayed increased IFN-γ responses in addition to enhanced recall responses even after multiple rounds of cell division (263, 264). They also display increased expression of NKG2C, NKG2A, CD69, and CD94, but not CD57 or KIR receptors (263). Due to the enhanced effector functions and relative ease at which CIML NK cells are generated, extensive study of the adoptive transfer of these cells, especially in the setting of myeloid malignancies, multiple myeloma, and head and neck squamous cell carcinoma has been undertaken (262). For example, infusion of 5 to 10 million cells/kg in patients with myeloid malignancies on lymphocyte depleting chemotherapy displayed a 10 to 50 fold expansion of NK cells that was determined to be independent of CMV reactivation and persisted for months (265). Other phase 1 studies of adoptively transferred CIML NK cells has also documented clinical responses. In the setting of acute myeloid leukemia, one study found clinical responses in 5 of 9 patients, of which included 4 complete remissions (259). Another study found complete remission in 4 of 8 patients (266), and when supported with 3 weeks of N-803 an 87% complete response rate was achieved by day 28 in a different study (267). The adoptive transfer of CIML NK cells has been understudied as a possible treatment for viral infections, and preclinical work, especially in the setting of HIV should be prioritized.

3.5 IL-15 superagonist therapy

Due to the aforementioned benefit of IL-15 stimulation on NK cell effector functions, novel approaches to enhance IL-15 signaling in vivo have been investigated. One such therapeutic is the IL-15 superagonist ALT-803. In SIV-positive rhesus macaques, ALT-803 (now N-803), an IL-15 superagonist comprised of an N72D mutant IL-15 molecule attached to its alpha receptor and a human IgG1 fragment designed to increase IL-15 activity, was shown to increase the NK cell population in the peripheral blood and decreased viral loads (268). In SHIV-infected rhesus macaques, N-803 was shown to mediate migration of virus-specific CD8+ T and NK cells to B-cell follicles, however no latency reversal was observed (269). A recent phase-1 clinical trial of N-803, showed that this molecule is also safe and tolerable in people living with HIV that are ART-suppressed. Further, N-803 was associated with CD8⁺ T and NK cell activation, as well as induced HIV RNA expression, with concurrent reduction in HIV DNA in Lymphoid tissue over time (270). Future clinical trials are needed to test the effects of these molecules on HIV reservoirs due to the promising results of the aforementioned preclinical and phase 1 studies.

3.6 NK cell engagers

As mentioned above, viral infections, especially HIV, can deter the natural recognition of virally infected cells by NK cells due to the manipulation of activating and inhibitory receptors expressed by the infected cell, thereby evading the immune response (82, 86, 87, 90–95). Broadly neutralizing antibodies (bnAbs) have been identified to play a role in viral control (271), and are used as a treatment and prevention strategy (272, 273).

Furthermore, in the RV144 HIV vaccine trial, which showed a statistically significant decrease in HIV infection risk (274), one correlate of reduced risk was found to be increased IgG antibodies targeting the V1V2 loop of the HIV ENV protein (275, 276). In a follow-up analysis, it was shown that these IgG antibodies elicited Fc-mediated NK cell ADCC functions (277, 278). These data suggest that non-neutralizing antibodies play a role in HIV protection through mediating effective Fc-effector functions (279–281). Additionally, NK cell-mediated ADCC against HIV has been noted as an important mechanism for HIV control (282–284), despite NK cell dysfunction (75, 113). However, a major concern with HIV-specific bnAbs is that HIV mutates rapidly and can escape bnAb-mediated neutralization (285–288). Further, the majority of bnAbs, which are generally of the IgG1 isotype, have good neutralization capacity, but subpar Fc-effector functions compared to their IgG3 isotypes (289–291).

Engineered small molecules are a promising strategy to direct NK cell mediated killing. The cancer field has made great progress in this field with the development of NK cell engagers (NKCE), Bi- and Tri– specific killer engagers (BiKEs and TriKEs™) as well as multi-specific antibody-based constructs (ANKET and StitchMabs) (292–297), which bind to activating receptors on NK cells. Briefly, TriKEs™ consist of an anti-CD16 engaging molecule that directly binds the CD16 receptor, joined via a flexible linker to an IL-15 molecule, and in-turn joined via linkers to an antigen engaging molecule to target an antigen of interest (298). Similarly, BiKEs consist of a similar anti-CD16 engaging molecule that is joined via a linker to an analogous antigen engaging molecule (298). ANKET constructs consist of an Fab that targets an NK cell receptor, commonly NKp46, together with another Fab that targets an antigen of interest (292). As alluded to above, ANKET molecules can also be generated to display bivalent binding to one or two different antigens (292). Furthermore, T-cell based nano engagers have also been developed in the form of Bi-specific T cell engagers (BiTEs) (299), and dual affinity retargeting antibodies (DARTs) (300, 301), although this is outside the scope of this review and won’t be discussed further here.

If we consider these therapies for HIV infection, many of the NK cell engagers mentioned above use either NKp46 or CD16 as the NK cell engaging molecule. However, NK cells are dysregulated during HIV infection, with activating and inhibitory receptor expression modulated. Importantly, despite NK cell dysfunction during HIV infection, NK cells still retain expression of CD16, enabling them to mediate ADCC (82). Therefore, given NK dysfunction, the retention of CD16 and the importance of Fc-mediated effector functions to combat HIV, strategies that exploit these are promising. Engineered small molecules that can bind directly to NK cells via CD16 interaction have been recently developed (302). This has been achieved by utilizing the BiKE and TriKE™ constructs that had previously been designed to target cancers (303–308).

These molecules allow the targeting of a variety of antigens for multiple viral infections, while also mitigating potential issues that arise with Fc-mediated effector functions. Further the IL-15 molecule induces persistence, expansion, and activation of NK cells (257). Currently, a BiKE construct has been generated using the HIV binding region of the VRC01 bnAb. This VRC01 BiKE construct, was shown to bind the HIV infected cell lines HIV-IIIB and ACH-2, but not their uninfected counterparts H9 or CEMs. Further, this VRC01 BiKE mediated effective NK activation, assessed by degranulation via CD107a expression and IFN-γ and TNF-α cytokine production, and subsequent killing against these HIV infected cells (309). Further work generating and testing TriKE constructs making use of the VRC01 binding region as well as other known HIV bnAb binding regions is currently underway.

However, HIV can escape viral restriction via bnAbs, so breadth is an important consideration in the development of novel therapeutics. Importantly, all HIV variants must utilize the CD4 receptor for initial gp120 binding to the cell surface (310). Therefore, using the CD4 receptor as the HIV binding region in novel therapeutics could overcome HIV escape (285). However, as this is a naturally found receptor used by many cells, careful consideration must be taken in the design so not to induce self-targeting. Extensive work in this field has already been done (311–313), and a CD4 extracellular domain 1 (CD4ECD1) molecule, designated mD1.22, with potent HIV neutralization and little binding to MHC class 2 has been identified (314). When designed into a BiKE construct with CD16 binding capabilities, it induced NK cell degranulation and killed HIV target cells (315). A CD4ECD1 TRiKE is currently in development and testing. Further, these TriKEs can be used in combination with a checkpoint inhibitor therapy (308), or other cytokine based or adoptive NK transfer strategies, highlighting the vast potential of these NK cell engagers for combination therapies to combat viral infections.

3.7 CAR NK cells

Chimeric antigen receptor (CAR) cells are another promising treatment that have been popular in the cancer field for many years and are now starting to be studied as a potential therapeutic for viral diseases. Many researchers have begun to produce CAR NK cells as they are less expensive and less likely to cause cytokine storm than CAR T cells (316). One such example is a CAR-NK cell therapy that secretes IL-15 and expresses a CAR with an extracellular ACE2 domain to target the SARS-CoV-2 spike protein and has been promising against SARS-CoV-2 in vitro (317). There is also currently another clinical trial underway to test a CAR NK cell that expresses ACE2 on it surface to treat severe COVID-19 patients (NCT04324996).

CAR NK cells are also currently being used in a clinical trial to treat HIV (318). In the setting of HIV, CAR-NK cells have largely targeted a single epitope of the HIV envelope glycoprotein gp160. Recently, the development of universal CAR-NK cells that target a broader range of gp160 has shown greater activation and the ability to kill HIV infected human CD4⁺ T cells (319). A visual overview of the discussed therapeutics is available in Figure 7.

Figure 7

4 Perspective on the use of NK cell therapies during viral infection

As described above, several lines of therapeutics including TGF- β inhibitors, adoptive cell therapies, cytokine therapies, NK cell engagers, and CAR NK cells have emerged in an effort to remedy NK cell dysregulation. While many of these therapeutics have been primarily tested in the setting cancer, they deserve further attention as possible remedies to preserve and restore NK cells function in the setting of viral infection. Furthermore, testing of these therapies in conjunction with each other as well as other therapeutics may prove particularly beneficial due to possible synergism.

Due to the extensive genetic differences present in NK cell receptors like the KIR family and ligands like HLA (31–33, 37), it is likely that there is also significant variation in the efficacy of these therapeutics depending on an individual’s personal repertoire of receptor and ligand genes. One of the clearest examples of this can be found in the case of KIR checkpoint inhibitors like IPH4102. Due to extensive variability in individuals’ KIR repertoire, responses to therapy between patients are also very variable, with only a subset achieving clinical responses (232). Similar variability in responses should be anticipated for the other therapeutics discussed here due to genetic variability in other NK cell receptors and ligands. Another consideration is that many of these therapeutics also run the risk of contributing to tissue damage and hyperinflammatory states by enhancing NK cell cytotoxic action and secretion of proinflammatory cytokines. Nonetheless, there may prove to be a balance between this risk and possible therapeutic benefit.

5 Concluding remarks

While NK cells play an important role in responding early to viral challenges, they can be dysregulated. This dysregulation, whether it be related to alterations in the prevalence of activating or inhibitory receptors, relative maturation in terms of subset prevalence, expression of functional effector proteins, or a product of an individual’s receptor and HLA genetics limits their ability to mount an effective antiviral response. For example, during chronic HIV and HCV, as well as acute SARS-CoV-2 there is an inherent depletion in the total prevalence of CD56⁺ CD16⁺ NK cells in the peripheral blood which is accompanied by markedly increased NK cell exhaustion. In contrast, aberrant NK cell activation in response to viral infection can also result in a direct contribution to viral disease pathogenesis by mediating excessive tissue damage, as was described as possibly being the case in some select influenza viruses.

While significant work has been done characterizing the NK cell repertoire correlated with disease state, less work has been done regarding elucidating the signaling environment that leads to changes in the NK cell population in vivo. As discussed, while cytokines like TGF-β are known to alter NK cell phenotype and function, the full landscape of signaling that leads to disease-specific NK cell repertoire requires more broad characterization. This rings especially true when considering the extensive genetic variability present in both HLA and important receptor families such as the KIR receptor family. The significant genetic variance in terms of NK cell repertoire and the subsequent corresponding differences in affinity between NK cell receptors and their ligands renders it extremely difficult to elucidate relationships between NK cell repertoire and disease. In essence, the state of an NK cell response, is determined not just by the relative expression of these receptors and their ligands, but by their genetic content and the relative receptor-ligand affinity it institutes. Despite these limitations, early preclinical and clinical work testing therapeutics seeking to address the changes in NK cell repertoire and activity associated with viral infection remains promising (Figure 8).

Figure 8

References

• 1

  Vivier E Tomasello E Baratin M Walzer T Ugolini S . Functions of natural killer cells. Nat Immunol (2008) 9(5):503–10. doi: 10.1038/ni1582

  • CrossRef
  • Google Scholar

• 2

  Wu Y Tian Z Wei H . Developmental and functional control of natural killer cells by cytokines. Front Immunol (2017) 8:930. doi: 10.3389/fimmu.2017.00930

  • CrossRef
  • Google Scholar

• 3

  Biron CA Byron KS Sullivan JL . Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med (1989) 320(26):1731–5. doi: 10.1056/NEJM198906293202605

  • CrossRef
  • Google Scholar

• 4

  Orange JS . Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol (2006) 6(6):399–409. doi: 10.1097/ACI.0b013e3280106b65

  • CrossRef
  • Google Scholar

• 5

  Orange JS . Natural killer cell deficiency. J Allergy Clin Immunol (2013) 132(3):515–25. doi: 10.1016/j.jaci.2013.07.020

  • CrossRef
  • Google Scholar

• 6

  Yu J Freud AG Caligiuri MA . Location and cellular stages of natural killer cell development. Trends Immunol (2013) 34(12):573–82. doi: 10.1016/j.it.2013.07.005

  • CrossRef
  • Google Scholar

• 7

  Cooper MA Fehniger TA Caligiuri MA . The biology of human natural killer-cell subsets. Trends Immunol (2001) 22(11):633–40. doi: 10.1016/S1471-4906(01)02060-9

  • CrossRef
  • Google Scholar

• 8

  Poli A Michel T Thérésine M Andrès E Hentges F Zimmer J . CD56bright natural killer (NK) cells: an important NK cell subset. Immunology (2009) 126(4):458–65. doi: 10.1111/j.1365-2567.2008.03027.x

  • CrossRef
  • Google Scholar

• 9

  Carson WE Fehniger TA Caligiuri MA . CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol (1997) 27(2):354–60. doi: 10.1002/eji.1830270203

  • CrossRef
  • Google Scholar

• 10

  Chan A Hong DL Atzberger A Kollnberger S Filer AD Buckley CD et al . CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol (2007) 179(1):89–94. doi: 10.4049/jimmunol.179.1.89

  • CrossRef
  • Google Scholar

• 11

  Jacobs R Hintzen G Kemper A Beul K Kempf S Behrens G et al . CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol (2001) 31(10):3121–7. doi: 10.1002/1521-4141(2001010)31:10<3121::AID-IMMU3121>3.0.CO;2-4

  • CrossRef
  • Google Scholar

• 12

  Capuano C Pighi C Battella S De Federicis D Galandrini R Palmieri G . Harnessing CD16-mediated NK cell functions to enhance therapeutic efficacy of tumor-targeting mAbs. Cancers (Basel) (2021) 13(10):2500. doi: 10.3390/cancers13102500

  • CrossRef
  • Google Scholar

• 13

  De Maria A Bozzano F Cantoni C Moretta L . Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci USA (2011) 108(2):728–32. doi: 10.1073/pnas.1012356108

  • CrossRef
  • Google Scholar

• 14

  Mujal AM Delconte RB Sun JC . Natural killer cells: from innate to adaptive features. Annu Rev Immunol (2021) 39:417–47. doi: 10.1146/annurev-immunol-101819-074948

  • CrossRef
  • Google Scholar

• 15

  Franklin M Connolly E Hussell T . Recruited and tissue-resident natural killer cells in the lung during infection and cancer. Front Immunol (2022) 13:887503. doi: 10.3389/fimmu.2022.887503

  • CrossRef
  • Google Scholar

• 16

  Topham NJ Hewitt EW . Natural killer cell cytotoxicity: how do they pull the trigger? Immunology (2009) 128(1):7–15. doi: 10.1111/j.1365-2567.2009.03123.x

  • CrossRef
  • Google Scholar

• 17

  Ferez M Knudson CJ Lev A Wong EB Alves-Peixoto P Tang L et al . Viral infection modulates Qa-1b in infected and bystander cells to properly direct NK cell killing. J Exp Med (2021) 218(5):e20201782. doi: 10.1084/jem.20201782

  • CrossRef
  • Google Scholar

• 18

  Kaürre K Ljunggren HG Piontek G Kiessling R . Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 319(6055):675–8. doi: 10.1038/319675a0

  • CrossRef
  • Google Scholar

• 19

  Chester C Fritsch K Kohrt HE . Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy. Front Immunol (2015) 6:601. doi: 10.3389/fimmu.2015.00601

  • CrossRef
  • Google Scholar

• 20

  Raulet DH Guerra N . Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol (2009) 9(8):568–80. doi: 10.1038/nri2604

  • CrossRef
  • Google Scholar

• 21

  Sivori S Cantoni C Parolini S Marcenaro E Conte R Moretta L et al . IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol (2003) 33(12):3439–47. doi: 10.1002/eji.200324533

  • CrossRef
  • Google Scholar

• 22

  Cifaldi L Doria M Cotugno N Zicari S Cancrini C Palma P et al . DNAM-1 activating receptor and its ligands: how do viruses affect the NK cell-mediated immune surveillance during the various phases of infection? Int J Mol Sci (2019) 20(15):3715. doi: 10.3390/ijms20153715

  • CrossRef
  • Google Scholar

• 23

  Middleton D Curran M Maxwell L . Natural killer cells and their receptors. Transpl Immunol (2002) 10(2-3):147–64. doi: 10.1016/S0966-3274(02)00062-X

  • CrossRef
  • Google Scholar

• 24

  Blunt MD Khakoo SI . Activating killer cell immunoglobulin-like receptors: Detection, function and therapeutic use. Int J Immunogenet (2020) 47(1):1–12. doi: 10.1111/iji.12461

  • CrossRef
  • Google Scholar

• 25

  Waggoner SN Kumar V . Evolving role of 2B4/CD244 in T and NK cell responses during virus infection. Front Immunol (2012) 3:377. doi: 10.3389/fimmu.2012.00377

  • CrossRef
  • Google Scholar

• 26

  Wang X Xiong H Ning Z . Implications of NKG2A in immunity and immune-mediated diseases. Front Immunol (2022) 13:960852. doi: 10.3389/fimmu.2022.960852

  • CrossRef
  • Google Scholar

• 27

  Khan M Arooj S Wang H . NK cell-based immune checkpoint inhibition. Front Immunol (2020) 11:16. doi: 10.3389/fimmu.2020.00167

  • CrossRef
  • Google Scholar

• 28

  Béziat V Descours B Parizot C Debré P Vieillard V . NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PloS One (2010) 5(8):e11966. doi: 10.1371/journal.pone.0011966

  • CrossRef
  • Google Scholar

• 29

  Quatrini L Mariotti FR Munari E Tumino N Vacca P Moretta L . The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy. Cancers (Basel) (2020) 12(11):3285. doi: 10.3390/cancers12113285

  • CrossRef
  • Google Scholar

• 30

  Anderson AC Joller N Kuchroo VK . Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity (2016) 44(5):989–1004. doi: 10.1016/j.immuni.2016.05.001

  • CrossRef
  • Google Scholar

• 31

  Pende D Falco M Vitale M Cantoni C Vitale C Munari E et al . Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front Immunol (2019) 10:1179. doi: 10.3389/fimmu.2019.01179

  • CrossRef
  • Google Scholar

• 32

  Dubreuil L Chevallier P Retière C Gagne K . Relevance of polymorphic KIR and HLA class I genes in NK-cell-based immunotherapies for adult leukemic patients. Cancers (Basel) (2021) 13(15):3767. doi: 10.3390/cancers13153767

  • CrossRef
  • Google Scholar

• 33

  Yawata M Yawata N Abi-Rached L Parham P . Variation within the human killer cell immunoglobulin-like receptor (KIR) gene family. Crit Rev Immunol (2002) 22(5-6):463–82. doi: 10.1615/CritRevImmunol.v22.i5-6.70

  • CrossRef
  • Google Scholar

• 34

  Norman PJ Stephens HA Verity DH Chandanayingyong D Vaughan RW . Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups. Immunogenetics (2001) 52(3-4):195–205. doi: 10.1007/s002510000281

  • CrossRef
  • Google Scholar

• 35

  Shilling HG Guethlein LA Cheng NW Gardiner CM Rodriguez R Tyan D et al . Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol (2002) 168(5):2307–15. doi: 10.4049/jimmunol.168.5.2307

  • CrossRef
  • Google Scholar

• 36

  Uhrberg M Valiante NM Shum BP Shilling HG Lienert-Weidenbach K Corliss B et al . Human diversity in killer cell inhibitory receptor genes. Immunity (1997) 7(6):753–63. doi: 10.1016/S1074-7613(00)80394-5

  • CrossRef
  • Google Scholar

• 37

  Barker DJ Maccari G Georgiou X Cooper MA Flicek P Robinson J et al . The IPD-IMGT/HLA database. Nucleic Acids Res (2023) 51(D1):D1053–D60. doi: 10.1093/nar/gkac1011

  • CrossRef
  • Google Scholar

• 38

  Yawata M Yawata N Draghi M Little AM Partheniou F Parham P . Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med (2006) 203(3):633–45. doi: 10.1084/jem.20051884

  • CrossRef
  • Google Scholar

• 39

  Winter CC Gumperz JE Parham P Long EO Wagtmann N . Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol (1998) 161(2):571–7. doi: 10.4049/jimmunol.161.2.571

  • CrossRef
  • Google Scholar

• 40

  Dubreuil L Maniangou B Chevallier P Quéméner A Legrand N Béné MC et al . Centromeric KIR AA individuals harbor particular KIR alleles conferring beneficial NK cell features with implications in haplo-identical hematopoietic stem cell transplantation. Cancers (Basel) (2020) 12(12):3595. doi: 10.3390/cancers12123595

  • CrossRef
  • Google Scholar

• 41

  Alter G Heckerman D Schneidewind A Fadda L Kadie CM Carlson JM et al . HIV-1 adaptation to NK-cell-mediated immune pressure. Nature (2011) 476(7358):96–100. doi: 10.1038/nature10237

  • CrossRef
  • Google Scholar

• 42

  Hölzemer A Thobakgale CF Jimenez Cruz CA Garcia-Beltran WF Carlson JM van Teijlingen NH et al . Selection of an HLA-C*03:04-restricted HIV-1 p24 Gag sequence variant is associated with viral escape from KIR2DL3+ Natural killer cells: data from an observational cohort in South Africa. PloS Med (2015) 12(11):e1001900. doi: 10.1371/journal.pmed.1001900

  • CrossRef
  • Google Scholar

• 43

  Khakoo SI Thio CL Martin MP Brooks CR Gao X Astemborski J et al . HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 305(5685):872–4. doi: 10.1126/science.1097670

  • CrossRef
  • Google Scholar

• 44

  Littera R Chessa L Deidda S Angioni G Campagna M Lai S et al . Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection. PloS One (2021) 16(8):e0255608. doi: 10.1371/journal.pone.0255608

  • CrossRef
  • Google Scholar

• 45

  Wauquier N Padilla C Becquart P Leroy E Vieillard V . Association of KIR2DS1 and KIR2DS3 with fatal outcome in Ebola virus infection. Immunogenetics (2010) 62(11-12):767–71. doi: 10.1007/s00251-010-0480-x

  • CrossRef
  • Google Scholar

• 46

  Hayashi T Imai K Morishita Y Hayashi I Kusunoki Y Nakachi K . Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res (2006) 66(1):563–70. doi: 10.1158/0008-5472.CAN-05-2776

  • CrossRef
  • Google Scholar

• 47

  Hara R Onizuka M Matsusita E Kikkawa E Nakamura Y Matsushita H et al . NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib. Int J Hematol (2017) 106(5):666–74. doi: 10.1007/s12185-017-2294-1

  • CrossRef
  • Google Scholar

• 48

  Zingoni A Molfetta R Fionda C Soriani A Paolini R Cippitelli M et al . NKG2D and its ligands: “One for all, all for one”. Front Immunol (2018) 9:476. doi: 10.3389/fimmu.2018.00476

  • CrossRef
  • Google Scholar

• 49

  Khor CC Chau TN Pang J Davila S Long HT Ong RT et al . Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat Genet (2011) 43(11):1139–41. doi: 10.1038/ng.960

  • CrossRef
  • Google Scholar

• 50

  Dang TN Naka I Sa-Ngasang A Anantapreecha S Chanama S Wichukchinda N et al . A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome. BMC Med Genet (2014) 15:58. doi: 10.1186/1471-2350-15-58

  • CrossRef
  • Google Scholar

• 51

  Ding W Ma Y Zhu W Pu W Zhang J Qian F et al . Allele facilitates the metastasis of KRAS-mutant colorectal cancer. Front Genet (2020) 11:511. doi: 10.3389/fgene.2020.00511

  • CrossRef
  • Google Scholar

• 52

  Tamaki S Sanefuzi N Ohgi K Imai Y Kawakami M Yamamoto K et al . An association between the MICA-A5.1 allele and an increased susceptibility to oral squamous cell carcinoma in Japanese patients. J Oral Pathol Med (2007) 36(6):351–6. doi: 10.1111/j.1600-0714.2007.00539.x

  • CrossRef
  • Google Scholar

• 53

  Tamaki S Kawakami M Yamanaka Y Shimomura H Imai Y Ishida J et al . Relationship between soluble MICA and the MICA A5.1 homozygous genotype in patients with oral squamous cell carcinoma. Clin Immunol (2009) 130(3):331–7. doi: 10.1016/j.clim.2008.09.004

  • CrossRef
  • Google Scholar

• 54

  Lavado-Valenzuela R Benavides M Carabantes F Alonso A Caballero A . MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer. Tissue Antigens (2009) 74(1):46–9. doi: 10.1111/j.1399-0039.2009.01254.x

  • CrossRef
  • Google Scholar

• 55

  Jumnainsong A Romphruk AV Jearanaikoon P Klumkrathok K Romphruk A Luanrattanakorn S et al . Association of polymorphic extracellular domains of MICA with cervical cancer in northeastern Thai population. Tissue Antigens (2007) 69(4):326–33. doi: 10.1111/j.1399-0039.2006.00754.x

  • CrossRef
  • Google Scholar

• 56

  Kared H Martelli S Ng TP Pender SL Larbi A . CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother (2016) 65(4):441–52. doi: 10.1007/s00262-016-1803-z

  • CrossRef
  • Google Scholar

• 57

  Borrego F Robertson MJ Ritz J Peña J Solana R . CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology (1999) 97(1):159–65. doi: 10.1046/j.1365-2567.1999.00738.x

  • CrossRef
  • Google Scholar

• 58

  Marden CM North J Anderson R Bakhsh IA Addison E Pittman H et al . CD69 is required for activated NK cell-mediated killing of resistant targets. Blood (2005) 106(11):3322–. doi: 10.1182/blood.V106.11.3322.3322

  • CrossRef
  • Google Scholar

• 59

  Hashemi E Malarkannan S . Tissue-resident NK cells: development, maturation, and clinical relevance. Cancers (Basel) (2020) 12(6):1553. doi: 10.3390/cancers12061553

  • CrossRef
  • Google Scholar

• 60

  Alter G Malenfant JM Altfeld M . CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods (2004) 294(1-2):15–22. doi: 10.1016/j.jim.2004.08.008

  • CrossRef
  • Google Scholar

• 61

  Velotti F Barchetta I Cimini FA Cavallo MG . Granzyme B in inflammatory diseases: apoptosis, inflammation, extracellular matrix remodeling, epithelial-to-mesenchymal transition and fibrosis. Front Immunol (2020) 11:587581. doi: 10.3389/fimmu.2020.587581

  • CrossRef
  • Google Scholar

• 62

  Osińska I Popko K Demkow U . Perforin: an important player in immune response. Cent Eur J Immunol (2014) 39(1):109–15. doi: 10.5114/ceji.2014.42135

  • CrossRef
  • Google Scholar

• 63

  Yoon SR Kim TD Choi I . Understanding of molecular mechanisms in natural killer cell therapy. Exp Mol Med (2015) 47(2):e141. doi: 10.1038/emm.2014.114

  • CrossRef
  • Google Scholar

• 64

  Lo Nigro C Macagno M Sangiolo D Bertolaccini L Aglietta M Merlano MC . NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann Transl Med (2019) 7(5):105. doi: 10.21037/atm.2019.01.42

  • CrossRef
  • Google Scholar

• 65

  Engelman A Cherepanov P . The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol (2012) 10(4):279–90. doi: 10.1038/nrmicro2747

  • CrossRef
  • Google Scholar

• 66

  Deeks SG Overbaugh J Phillips A Buchbinder S . HIV infection. Nat Rev Dis Primers (2015) 1:15035. doi: 10.1038/nrdp.2015.35

  • CrossRef
  • Google Scholar

• 67

  Cohn LB Chomont N Deeks SG . The biology of the HIV-1 latent reservoir and implications for cure strategies. Cell Host Microbe (2020) 27(4):519–30. doi: 10.1016/j.chom.2020.03.014

  • CrossRef
  • Google Scholar

• 68

  Douglas SD Durako SJ Tustin NB Houser J Muenz L Starr SE et al . Natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescents. AIDS Res Hum Retroviruses (2001) 17(6):543–52. doi: 10.1089/08892220151126643

  • CrossRef
  • Google Scholar

• 69

  Tarazona R Casado JG Delarosa O Torre-Cisneros J Villanueva JL Sanchez B et al . Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol (2002) 22(3):176–83. doi: 10.1023/A:1015476114409

  • CrossRef
  • Google Scholar

• 70

  Hong HS Eberhard JM Keudel P Bollmann BA Ballmaier M Bhatnagar N et al . HIV infection is associated with a preferential decline in less-differentiated CD56dim CD16+ NK cells. J Virol (2010) 84(2):1183–8. doi: 10.1128/JVI.01675-09

  • CrossRef
  • Google Scholar

• 71

  Slyker JA Lohman-Payne B John-Stewart GC Dong T Mbori-Ngacha D Tapia K et al . The impact of HIV-1 infection and exposure on natural killer (NK) cell phenotype in Kenyan infants during the first year of life. Front Immunol (2012) 3:399. doi: 10.3389/fimmu.2012.00399

  • CrossRef
  • Google Scholar

• 72

  Hong HS Ahmad F Eberhard JM Bhatnagar N Bollmann BA Keudel P et al . Loss of CCR7 expression on CD56(bright) NK cells is associated with a CD56(dim)CD16(+) NK cell-like phenotype and correlates with HIV viral load. PloS One (2012) 7(9):e44820. doi: 10.1371/journal.pone.0044820

  • CrossRef
  • Google Scholar

• 73

  Dierks P Wroblewski R Eberhard JM Martrus G Degen O Hertling S et al . Brief report: increased frequency of CD39+ CD56bright natural killer cells in HIV-1 infection correlates with immune activation and disease progression. J Acquir Immune Defic Syndr (2017) 74(4):467–72. doi: 10.1097/QAI.0000000000001266

  • CrossRef
  • Google Scholar

• 74

  Jiang Y Yang M Sun X Chen X Ma M Yin X et al . IL-10(+) NK and TGF-beta(+) NK cells play negative regulatory roles in HIV infection. BMC Infect Dis (2018) 18(1):80. doi: 10.1186/s12879-018-2991-2

  • CrossRef
  • Google Scholar

• 75

  Cao WJ Zhang XC Wan LY Li QY Mu XY Guo AL et al . Immune dysfunctions of CD56(neg) NK cells are associated with HIV-1 disease progression. Front Immunol (2021) 12:811091. doi: 10.3389/fimmu.2021.811091

  • CrossRef
  • Google Scholar

• 76

  Milush JM López-Vergès S York VA Deeks SG Martin JN Hecht FM et al . CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology (2013) 10:158. doi: 10.1186/1742-4690-10-158

  • CrossRef
  • Google Scholar

• 77

  Cocker ATH Liu F Djaoud Z Guethlein LA Parham P . CD56-negative NK cells: Frequency in peripheral blood, expansion during HIV-1 infection, functional capacity, and KIR expression. Front Immunol (2022) 13:992723. doi: 10.3389/fimmu.2022.992723

  • CrossRef
  • Google Scholar

• 78

  Mavilio D Lombardo G Benjamin J Kim D Follman D Marcenaro E et al . Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA (2005) 102(8):2886–91. doi: 10.1073/pnas.0409872102

  • CrossRef
  • Google Scholar

• 79

  Ma M Yin X Zhao X Guo C Zhu X Liu T et al . CD56(-) CD16(+) NK cells from HIV-infected individuals negatively regulate IFN-gamma production by autologous CD8(+) T cells. J Leukoc Biol (2019) 106(6):1313–23. doi: 10.1002/JLB.3A0819-171RR

  • CrossRef
  • Google Scholar

• 80

  Cocker ATH Guethlein LA Parham P . The CD56-CD16+ NK cell subset in chronic infections. Biochem Soc Trans (2023) 51(3):1201–12. doi: 10.1042/BST20221374

  • CrossRef
  • Google Scholar

• 81

  Zhang Z Zhou Y Lu J Chen YF Hu HY Xu XQ et al . Changes in NK cell subsets and receptor expressions in HIV-1 infected chronic patients and HIV controllers. Front Immunol (2021) 12:792775. doi: 10.3389/fimmu.2021.792775

  • CrossRef
  • Google Scholar

• 82

  Mavilio D Benjamin J Daucher M Lombardo G Kottilil S Planta MA et al . Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci USA (2003) 100(25):15011–6. doi: 10.1073/pnas.2336091100

  • CrossRef
  • Google Scholar

• 83

  Mahapatra S Shearer WT Minard CG Mace E Paul M Orange JS . NK cells in treated HIV-infected children display altered phenotype and function. J Allergy Clin Immunol (2019) 144(1):294–303 e13. doi: 10.1016/j.jaci.2018.11.052

  • CrossRef
  • Google Scholar

• 84

  Dillon SM Lee EJ Bramante JM Barker E Wilson CC . The natural killer cell interferon-gamma response to bacteria is diminished in untreated HIV-1 infection and defects persist despite viral suppression. J Acquir Immune Defic Syndr (2014) 65(3):259–67. doi: 10.1097/01.qai.0000435603.50598.2b

  • CrossRef
  • Google Scholar

• 85

  Kaczmarek DJ Kokordelis P Kramer B Glassner A Wolter F Goeser F et al . Alterations of the NK cell pool in HIV/HCV co-infection. PloS One (2017) 12(4):e0174465. doi: 10.1371/journal.pone.0174465

  • CrossRef
  • Google Scholar

• 86

  Cohen GB Gandhi RT Davis DM Mandelboim O Chen BK Strominger JL et al . The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity (1999) 10(6):661–71. doi: 10.1016/S1074-7613(00)80065-5

  • CrossRef
  • Google Scholar

• 87

  Schwartz O Maréchal V Le Gall S Lemonnier F Heard JM . Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med (1996) 2(3):338–42. doi: 10.1038/nm0396-338

  • CrossRef
  • Google Scholar

• 88

  Apps R Del Prete GQ Chatterjee P Lara A Brumme ZL Brockman MA et al . HIV-1 Vpu mediates HLA-C downregulation. Cell Host Microbe (2016) 19(5):686–95. doi: 10.1016/j.chom.2016.04.005

  • CrossRef
  • Google Scholar

• 89

  Bachtel ND Umviligihozo G Pickering S Mota TM Liang H Del Prete GQ et al . HLA-C downregulation by HIV-1 adapts to host HLA genotype. PloS Pathog (2018) 14(9):e1007257. doi: 10.1371/journal.ppat.1007257

  • CrossRef
  • Google Scholar

• 90

  Ward J Davis Z DeHart J Zimmerman E Bosque A Brunetta E et al . HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PloS Pathog (2009) 5(10):e1000613. doi: 10.1371/journal.ppat.1000613

  • CrossRef
  • Google Scholar

• 91

  Richard J Sindhu S Pham TN Belzile JP Cohen EA . HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood (2010) 115(7):1354–63. doi: 10.1182/blood-2009-08-237370

  • CrossRef
  • Google Scholar

• 92

  Sakai K Dimas J Lenardo MJ . The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci USA (2006) 103(9):3369–74. doi: 10.1073/pnas.0509417103

  • CrossRef
  • Google Scholar

• 93

  Shah AH Sowrirajan B Davis ZB Ward JP Campbell EM Planelles V et al . Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe (2010) 8(5):397–409. doi: 10.1016/j.chom.2010.10.008

  • CrossRef
  • Google Scholar

• 94

  Davis ZB Cogswell A Scott H Mertsching A Boucau J Wambua D et al . A conserved HIV-1-derived peptide presented by HLA-E renders infected T-cells highly susceptible to attack by NKG2A/CD94-bearing natural killer cells. PloS Pathog (2016) 12(2):e1005421. doi: 10.1371/journal.ppat.1005421

  • CrossRef
  • Google Scholar

• 95

  Bonaparte MI Barker E . Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood (2004) 104(7):2087–94. doi: 10.1182/blood-2004-02-0696

  • CrossRef
  • Google Scholar

• 96

  Luteijn R Sciaranghella G van Lunzen J Nolting A Dugast AS Ghebremichael MS et al . Early viral replication in lymph nodes provides HIV with a means by which to escape NK-cell-mediated control. Eur J Immunol (2011) 41(9):2729–40. doi: 10.1002/eji.201040886

  • CrossRef
  • Google Scholar

• 97

  Guo AL Jiao YM Zhao QW Huang HH Deng JN Zhang C et al . Implications of the accumulation of CXCR5(+) NK cells in lymph nodes of HIV-1 infected patients. EBioMedicine (2022) 75:103794. doi: 10.1016/j.ebiom.2021.103794

  • CrossRef
  • Google Scholar

• 98

  George AF Luo X Neidleman J Hoh R Vohra P Thomas R et al . Deep phenotypic analysis of blood and lymphoid T and NK cells from HIV+ Controllers and ART-suppressed individuals. Front Immunol (2022) 13:803417. doi: 10.3389/fimmu.2022.803417

  • CrossRef
  • Google Scholar

• 99

  Sungur CM Wang Q Ozanturk AN Gao H Schmitz AJ Cella M et al . Human NK cells confer protection against HIV-1 infection in humanized mice. J Clin Invest (2022) 132(24):e162694. doi: 10.1172/JCI162694

  • CrossRef
  • Google Scholar

• 100

  Sips M Sciaranghella G Diefenbach T Dugast AS Berger CT Liu Q et al . Altered distribution of mucosal NK cells during HIV infection. Mucosal Immunol (2012) 5(1):30–40. doi: 10.1038/mi.2011.40

  • CrossRef
  • Google Scholar

• 101

  Vollmers S Lobermeyer A Niehrs A Fittje P Indenbirken D Nakel J et al . Host KIR/HLA-C genotypes determine HIV-mediated changes of the NK cell repertoire and are associated with vpu sequence variations impacting downmodulation of HLA-C. Front Immunol (2022) 13:922252. doi: 10.3389/fimmu.2022.922252

  • CrossRef
  • Google Scholar

• 102

  Olvera A Pérez-Álvarez S Ibarrondo J Ganoza C Lama JR Lucchetti A et al . The HLA-C*04: 01/KIR2DS4 gene combination and human leukocyte antigen alleles with high population frequency drive rate of HIV disease progression. AIDS (2015) 29(5):507–17. doi: 10.1097/QAD.0000000000000574

  • CrossRef
  • Google Scholar

• 103

  Merino AM Dugast AS Wilson CM Goepfert PA Alter G Kaslow RA et al . KIR2DS4 promotes HIV-1 pathogenesis: new evidence from analyses of immunogenetic data and natural killer cell function. PloS One (2014) 9(6):e99353. doi: 10.1371/journal.pone.0099353

  • CrossRef
  • Google Scholar

• 104

  Mhandire K Zijenah LS Tshabalala M Yindom LM Mlambo T Mhandire DZ et al . KIR and HLA-C genetic polymorphisms influence plasma IP-10 concentration in antiretroviral therapy-naive HIV-infected adult Zimbabweans. OMICS (2019) 23(2):111–8. doi: 10.1089/omi.2018.0147

  • CrossRef
  • Google Scholar

• 105

  Alter G Martin MP Teigen N Carr WH Suscovich TJ Schneidewind A et al . Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med (2007) 204(12):3027–36. doi: 10.1084/jem.20070695

  • CrossRef
  • Google Scholar

• 106

  Pelak K Need AC Fellay J Shianna KV Feng S Urban TJ et al . Copy number variation of KIR genes influences HIV-1 control. PloS Biol (2011) 9(11):e1001208. doi: 10.1371/annotation/7e17b146-a69c-4e83-9230-7340486d9dc8

  • CrossRef
  • Google Scholar

• 107

  Florez-Alvarez L Hernandez JC Zapata W . NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies. Front Immunol (2018) 9:2290.

  • Google Scholar

• 108

  Reeves RK Li H Jost S Blass E Li H Schafer JL et al . Antigen-specific NK cell memory in rhesus macaques. Nat Immunol (2015) 16(9):927–32. doi: 10.1038/ni.3227

  • CrossRef
  • Google Scholar

• 109

  Tiemessen CT Shalekoff S Meddows-Taylor S Schramm DB Papathanasopoulos MA Gray GE et al . Cutting Edge: Unusual NK cell responses to HIV-1 peptides are associated with protection against maternal-infant transmission of HIV-1. J Immunol (2009) 182(10):5914–8. doi: 10.4049/jimmunol.0900419

  • CrossRef
  • Google Scholar

• 110

  Tiemessen CT Shalekoff S Meddows-Taylor S Schramm DB Papathanasopoulos M Gray G et al . Natural killer cells that respond to human immunodeficiency virus type 1 (HIV-1) peptides are associated with control of HIV-1 infection. J Infect Dis (2010) 202(9):1444–53. doi: 10.1086/656535

  • CrossRef
  • Google Scholar

• 111

  Gondois-Rey F Cheret A Granjeaud S Mallet F Bidaut G Lecuroux C et al . NKG2C(+) memory-like NK cells contribute to the control of HIV viremia during primary infection: Optiprim-ANRS 147. Clin Transl Immunol (2017) 6(7):e150. doi: 10.1038/cti.2017.22

  • CrossRef
  • Google Scholar

• 112

  Jensen SS Hartling HJ Tingstedt JL Larsen TK Nielsen SD Pedersen C et al . HIV-specific ADCC improves after antiretroviral therapy and correlates with normalization of the NK cell phenotype. J Acquir Immune Defic Syndr (2015) 68(2):103–11. doi: 10.1097/QAI.0000000000000429

  • CrossRef
  • Google Scholar

• 113

  Nabatanzi R Bayigga L Cose S Rowland-Jones S Canderan G Joloba M et al . Aberrant natural killer (NK) cell activation and dysfunction among ART-treated HIV-infected adults in an African cohort. Clin Immunol (2019) 201:55–60. doi: 10.1016/j.clim.2019.02.010

  • CrossRef
  • Google Scholar

• 114

  Lichtfuss GF Cheng WJ Farsakoglu Y Paukovics G Rajasuriar R Velayudham P et al . Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol (2012) 189(3):1491–9. doi: 10.4049/jimmunol.1200458

  • CrossRef
  • Google Scholar

• 115

  Giuliani E Vassena L Di Cesare S Malagnino V Desimio MG Andreoni M et al . NK cells of HIV-1-infected patients with poor CD4(+) T-cell reconstitution despite suppressive HAART show reduced IFN-gamma production and high frequency of autoreactive CD56(bright) cells. Immunol Lett (2017) 190:185–93. doi: 10.1016/j.imlet.2017.08.014

  • CrossRef
  • Google Scholar

• 116

  Ashfaq UA Javed T Rehman S Nawaz Z Riazuddin S . An overview of HCV molecular biology, replication and immune responses. Virol J (2011) 8:161. doi: 10.1186/1743-422X-8-161

  • CrossRef
  • Google Scholar

• 117

  Revie D Salahuddin SZ . Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virol J (2011) 8:346. doi: 10.1186/1743-422X-8-346

  • CrossRef
  • Google Scholar

• 118

  Millman AJ Nelson NP Vellozzi C . Hepatitis C: review of the epidemiology, clinical care, and continued challenges in the direct acting antiviral era. Curr Epidemiol Rep (2017) 4(2):174–85. doi: 10.1007/s40471-017-0108-x

  • CrossRef
  • Google Scholar

• 119

  Amadei B Urbani S Cazaly A Fisicaro P Zerbini A Ahmed P et al . Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology (2010) 138(4):1536–45. doi: 10.1053/j.gastro.2010.01.006

  • CrossRef
  • Google Scholar

• 120

  Grebely J Prins M Hellard M Cox AL Osburn WO Lauer G et al . Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 12(5):408–14. doi: 10.1016/S1473-3099(12)70010-5

  • CrossRef
  • Google Scholar

• 121

  de Groen RA Groothuismink ZMA van Oord G Kootstra NA Janssen HLA Prins M et al . NK cells in self-limited HCV infection exhibit a more extensively differentiated, but not memory-like, repertoire. J Viral Hepat (2017) 24(11):917–26. doi: 10.1111/jvh.12716

  • CrossRef
  • Google Scholar

• 122

  Golden-Mason L Cox AL Randall JA Cheng L Rosen HR . Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology (2010) 52(5):1581–9. doi: 10.1002/hep.23896

  • CrossRef
  • Google Scholar

• 123

  Harrison RJ Ettorre A Little AM Khakoo SI . Association of NKG2A with treatment for chronic hepatitis C virus infection. Clin Exp Immunol (2010) 161(2):306–14. doi: 10.1111/j.1365-2249.2010.04169.x

  • CrossRef
  • Google Scholar

• 124

  Ji HF Wang J Yu L Niu JQ Ayana DA Jiang YF . High frequencies of CD158b+ NK cells are associated with persistent hepatitis C virus infections. Ann Hepatol (2013) 12(4):539–47. doi: 10.1016/S1665-2681(19)31337-7

  • CrossRef
  • Google Scholar

• 125

  Frias M Rivero-Juárez A Rodriguez-Cano D Camacho Á López-López P Risalde M et al . HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance. Sci Rep (2018) 8(1):659. doi: 10.1038/s41598-017-17531-7

  • CrossRef
  • Google Scholar

• 126

  Morishima C Paschal DM Wang CC Yoshihara CS Wood BL Yeo AE et al . Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology (2006) 43(3):573–80. doi: 10.1002/hep.21073

  • CrossRef
  • Google Scholar

• 127

  Dessouki O Kamiya Y Nagahama H Tanaka M Suzu S Sasaki Y et al . Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment. Biochem Biophys Res Commun (2010) 393(2):331–7. doi: 10.1016/j.bbrc.2010.02.008

  • CrossRef
  • Google Scholar

• 128

  Golden-Mason L Madrigal-Estebas L McGrath E Conroy MJ Ryan EJ Hegarty JE et al . Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut (2008) 57(8):1121–8. doi: 10.1136/gut.2007.130963

  • CrossRef
  • Google Scholar

• 129

  Zarife MA Reis EA Carmo TM Lopes GB Brandao EC Silva HR et al . Increased frequency of CD56Bright NK-cells, CD3-CD16+CD56- NK-cells and activated CD4+T-cells or B-cells in parallel with CD4+CDC25High T-cells control potentially viremia in blood donors with HCV. J Med Virol (2009) 81(1):49–59. doi: 10.1002/jmv.21340

  • CrossRef
  • Google Scholar

• 130

  Golden-Mason L Hahn YS Strong M Cheng L Rosen HR . Extracellular HCV-core protein induces an immature regulatory phenotype in NK cells: implications for outcome of acute infection. PloS One (2014) 9(7):e103219. doi: 10.1371/journal.pone.0103219

  • CrossRef
  • Google Scholar

• 131

  Cosgrove C Berger CT Kroy DC Cheney PC Ghebremichael M Aneja J et al . Chronic HCV infection affects the NK cell phenotype in the blood more than in the liver. PloS One (2014) 9(8):e105950. doi: 10.1371/journal.pone.0105950

  • CrossRef
  • Google Scholar

• 132

  Miot C Beaumont E Duluc D Le Guillou-Guillemette H Preisser L Garo E et al . IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells. Gut (2015) 64(9):1466–75. doi: 10.1136/gutjnl-2013-306604

  • CrossRef
  • Google Scholar

• 133

  Larochette V Miot C Poli C Beaumont E Roingeard P Fickenscher H et al . IL-26, a cytokine with roles in extracellular DNA-induced inflammation and microbial defense. Front Immunol (2019) 10:204. doi: 10.3389/fimmu.2019.00204

  • CrossRef
  • Google Scholar

• 134

  Nel I Lucar O Petitdemange C Beziat V Lapalus M Bedossa P et al . Accumulation of intrahepatic TNF-alpha-producing NKp44+ NK cells correlates with liver fibrosis and viral load in chronic HCV infection. Med (Baltimore) (2016) 95(19):e3678. doi: 10.1097/MD.0000000000003678

  • CrossRef
  • Google Scholar

• 135

  Maretti-Mira AC Salomon MP Hsu AM Dara L Golden-Mason L . Etiology of end-stage liver cirrhosis impacts hepatic natural killer cell heterogenicity. Front Immunol (2023) 14:1137034. doi: 10.3389/fimmu.2023.1137034

  • CrossRef
  • Google Scholar

• 136

  Lunemann S Malone DF Hengst J Port K Grabowski J Deterding K et al . Compromised function of natural killer cells in acute and chronic viral hepatitis. J Infect Dis (2014) 209(9):1362–73. doi: 10.1093/infdis/jit561

  • CrossRef
  • Google Scholar

• 137

  Alter G Jost S Rihn S Reyor LL Nolan BE Ghebremichael M et al . Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. J Hepatol (2011) 55(2):278–88. doi: 10.1016/j.jhep.2010.11.030

  • CrossRef
  • Google Scholar

• 138

  Zhang C Wang XM Li SR Twelkmeyer T Wang WH Zhang SY et al . NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun (2019) 10(1):1507. doi: 10.1038/s41467-019-09212-y

  • CrossRef
  • Google Scholar

• 139

  Spaan M van Oord G Kreefft K Hou J Hansen BE Janssen HL et al . Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment. J Infect Dis (2016) 213(2):216–23. doi: 10.1093/infdis/jiv391

  • CrossRef
  • Google Scholar

• 140

  Zhang X Jiang Y Li S Bian D Liu M Kong M et al . Direct-acting antiviral-induced transient recovery of NK cells in early-stage treatment of chronic hepatitis C patients. J Clin Transl Hepatol (2022) 10(6):1117–24. doi: 10.14218/JCTH.2021.00427

  • CrossRef
  • Google Scholar

• 141

  Mele D Oliviero B Mantovani S Ludovisi S Lombardi A Genco F et al . Adaptive natural killer cell functional recovery in hepatitis C virus cured patients. Hepatology (2021) 73(1):79–90. doi: 10.1002/hep.31273

  • CrossRef
  • Google Scholar

• 142

  Cunningham C Gatherer D Hilfrich B Baluchova K Dargan DJ Thomson M et al . Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens. J Gen Virol (2010) 91(Pt 3):605–15. doi: 10.1099/vir.0.015891-0

  • CrossRef
  • Google Scholar

• 143

  Wang YQ Zhao XY . Human cytomegalovirus primary infection and reactivation: insights from virion-carried molecules. Front Microbiol (2020) 11:1511. doi: 10.3389/fmicb.2020.01511

  • CrossRef
  • Google Scholar

• 144

  Lopez-Vergès S Milush JM Schwartz BS Pando MJ Jarjoura J York VA et al . Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA (2011) 108(36):14725–32. doi: 10.1073/pnas.1110900108

  • CrossRef
  • Google Scholar

• 145

  Foley B Cooley S Verneris MR Pitt M Curtsinger J Luo X et al . Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood (2012) 119(11):2665–74. doi: 10.1182/blood-2011-10-386995

  • CrossRef
  • Google Scholar

• 146

  Rolle A Brodin P . Immune adaptation to environmental influence: the case of NK cells and HCMV. Trends Immunol (2016) 37(3):233–43. doi: 10.1016/j.it.2016.01.005

  • CrossRef
  • Google Scholar

• 147

  Bayard C Lepetitcorps H Roux A Larsen M Fastenackels S Salle V et al . Coordinated expansion of both memory T cells and NK cells in response to CMV infection in humans. Eur J Immunol (2016) 46(5):1168–79. doi: 10.1002/eji.201546179

  • CrossRef
  • Google Scholar

• 148

  Hendricks DW Balfour HH Jr. Dunmire SK Schmeling DO Hogquist KA Lanier LL . Cutting edge: NKG2C(hi)CD57+ NK cells respond specifically to acute infection with cytomegalovirus and not Epstein-Barr virus. J Immunol (2014) 192(10):4492–6. doi: 10.4049/jimmunol.1303211

  • CrossRef
  • Google Scholar

• 149

  Djaoud Z David G Bressollette C Willem C Rettman P Gagne K et al . Amplified NKG2C+ NK cells in cytomegalovirus (CMV) infection preferentially express killer cell Ig-like receptor 2DL: functional impact in controlling CMV-infected dendritic cells. J Immunol (2013) 191(5):2708–16. doi: 10.4049/jimmunol.1301138

  • CrossRef
  • Google Scholar

• 150

  Campos C Lopez N Pera A Gordillo JJ Hassouneh F Tarazona R et al . Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age. Biogerontology (2015) 16(5):671–83. doi: 10.1007/s10522-015-9581-0

  • CrossRef
  • Google Scholar

• 151

  Beziat V Dalgard O Asselah T Halfon P Bedossa P Boudifa A et al . CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol (2012) 42(2):447–57. doi: 10.1002/eji.201141826

  • CrossRef
  • Google Scholar

• 152

  Costa-Garcia M Vera A Moraru M Vilches C Lopez-Botet M Muntasell A . Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus. J Immunol (2015) 194(6):2715–24. doi: 10.4049/jimmunol.1402281

  • CrossRef
  • Google Scholar

• 153

  Barnes S Schilizzi O Audsley KM Newnes HV Foley B . Deciphering the immunological phenomenon of adaptive natural killer (NK) cells and cytomegalovirus (CMV). Int J Mol Sci (2020) 21(22):8864. doi: 10.3390/ijms21228864

  • CrossRef
  • Google Scholar

• 154

  Cichocki F Miller JS Anderson SK Bryceson YT . Epigenetic regulation of NK cell differentiation and effector functions. Front Immunol (2013) 4:55. doi: 10.3389/fimmu.2013.00055

  • CrossRef
  • Google Scholar

• 155

  Schlums H Cichocki F Tesi B Theorell J Beziat V Holmes TD et al . Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity (2015) 42(3):443–56. doi: 10.1016/j.immuni.2015.02.008

  • CrossRef
  • Google Scholar

• 156

  Della Chiesa M Muccio L Moretta A . CMV induces rapid NK cell maturation in HSCT recipients. Immunol Lett (2013) 155(1-2):11–3. doi: 10.1016/j.imlet.2013.09.020

  • CrossRef
  • Google Scholar

• 157

  Hassan N Eldershaw S Stephens C Kinsella F Craddock C Malladi R et al . CMV reactivation initiates long-term expansion and differentiation of the NK cell repertoire. Front Immunol (2022) 13:935949. doi: 10.3389/fimmu.2022.935949

  • CrossRef
  • Google Scholar

• 158

  Storek J Dawson MA Storer B Stevens-Ayers T Maloney DG Marr KA et al . Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 97(11):3380–9. doi: 10.1182/blood.V97.11.3380

  • CrossRef
  • Google Scholar

• 159

  Foley B Cooley S Verneris MR Curtsinger J Luo X Waller EK et al . Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol (2012) 189(10):5082–8. doi: 10.4049/jimmunol.1201964

  • CrossRef
  • Google Scholar

• 160

  Steinhauer DA Skehel JJ . Genetics of influenza viruses. Annu Rev Genet (2002) 36:305–32. doi: 10.1146/annurev.genet.36.052402.152757

  • CrossRef
  • Google Scholar

• 161

  Bouvier NM Palese P . The biology of influenza viruses. Vaccine (2008) 26 Suppl 4(Suppl 4):D49–53. doi: 10.1016/j.vaccine.2008.07.039

  • CrossRef
  • Google Scholar

• 162

  Kalil AC Thomas PG . Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care (2019) 23(1):258. doi: 10.1186/s13054-019-2539-x

  • CrossRef
  • Google Scholar

• 163

  Brownlie D Rodahl I Varnaite R Asgeirsson H Glans H Falck-Jones S et al . Comparison of lung-homing receptor expression and activation profiles on NK cell and T cell subsets in COVID-19 and influenza. Front Immunol (2022) 13:834862. doi: 10.3389/fimmu.2022.834862

  • CrossRef
  • Google Scholar

• 164

  Carlin LE Hemann EA Zacharias ZR Heusel JW Legge KL . Natural killer cell recruitment to the lung during influenza A virus infection is dependent on CXCR3, CCR5, and virus exposure dose. Front Immunol (2018) 9:781. doi: 10.3389/fimmu.2018.00781

  • CrossRef
  • Google Scholar

• 165

  Verbist KC Rose DL Cole CJ Field MB Klonowski KD . IL-15 participates in the respiratory innate immune response to influenza virus infection. PloS One (2012) 7(5):e37539. doi: 10.1371/journal.pone.0037539

  • CrossRef
  • Google Scholar

• 166

  Fox A Le NM Horby P van Doorn HR Nguyen VT Nguyen HH et al . Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses. PloS One (2012) 7(2):e31535. doi: 10.1371/journal.pone.0031535

  • CrossRef
  • Google Scholar

• 167

  Jost S Quillay H Reardon J Peterson E Simmons RP Parry BA et al . Changes in cytokine levels and NK cell activation associated with influenza. PloS One (2011) 6(9):e25060. doi: 10.1371/journal.pone.0025060

  • CrossRef
  • Google Scholar

• 168

  Jost S Reardon J Peterson E Poole D Bosch R Alter G et al . Expansion of 2B4+ natural killer (NK) cells and decrease in NKp46+ NK cells in response to influenza. Immunology (2011) 132(4):516–26. doi: 10.1111/j.1365-2567.2010.03394.x

  • CrossRef
  • Google Scholar

• 169

  Juarez-Reyes A Noyola DE Monsivais-Urenda A Alvarez-Quiroga C Gonzalez-Amaro R . Influenza virus infection but not H1N1 influenza virus immunization is associated with changes in peripheral blood NK cell subset levels. Clin Vaccine Immunol (2013) 20(8):1291–7. doi: 10.1128/CVI.00194-13

  • CrossRef
  • Google Scholar

• 170

  Zheng J Wen L Yen HL Liu M Liu Y Teng O et al . Phenotypic and functional characteristics of a novel influenza virus hemagglutinin-specific memory NK cell. J Virol (2021) 95(12):e00165–21. doi: 10.1128/JVI.00165-21

  • CrossRef
  • Google Scholar

• 171

  Mao H Tu W Qin G Law HK Sia SF Chan PL et al . Influenza virus directly infects human natural killer cells and induces cell apoptosis. J Virol (2009) 83(18):9215–22. doi: 10.1128/JVI.00805-09

  • CrossRef
  • Google Scholar

• 172

  Mao H Liu Y Sia SF Peiris JSM Lau YL Tu W . Avian influenza virus directly infects human natural killer cells and inhibits cell activity. Virol Sin (2017) 32(2):122–9. doi: 10.1007/s12250-016-3918-y

  • CrossRef
  • Google Scholar

• 173

  Guo H Kumar P Moran TM Garcia-Sastre A Zhou Y Malarkannan S . The functional impairment of natural killer cells during influenza virus infection. Immunol Cell Biol (2009) 87(8):579–89. doi: 10.1038/icb.2009.60

  • CrossRef
  • Google Scholar

• 174

  Cooper GE Ostridge K Khakoo SI Wilkinson TMA Staples KJ . Human CD49a(+) lung natural killer cell cytotoxicity in response to influenza A virus. Front Immunol (2018) 9:1671. doi: 10.3389/fimmu.2018.01671

  • CrossRef
  • Google Scholar

• 175

  Du N Zhou J Lin X Zhang Y Yang X Wang Y et al . Differential activation of NK cells by influenza A pseudotype H5N1 and 1918 and 2009 pandemic H1N1 viruses. J Virol (2010) 84(15):7822–31. doi: 10.1128/JVI.00069-10

  • CrossRef
  • Google Scholar

• 176

  Scharenberg M Vangeti S Kekalainen E Bergman P Al-Ameri M Johansson N et al . Influenza A virus infection induces hyperresponsiveness in human lung tissue-resident and peripheral blood NK cells. Front Immunol (2019) 10:1116. doi: 10.3389/fimmu.2019.01116

  • CrossRef
  • Google Scholar

• 177

  Zhou G Juang SW Kane KP . NK cells exacerbate the pathology of influenza virus infection in mice. Eur J Immunol (2013) 43(4):929–38. doi: 10.1002/eji.201242620

  • CrossRef
  • Google Scholar

• 178

  Jansen CA de Geus ED van Haarlem DA van de Haar PM Löndt BZ Graham SP et al . Differential lung NK cell responses in avian influenza virus infected chickens correlate with pathogenicity. Sci Rep (2013) 3:2478. doi: 10.1038/srep02478

  • CrossRef
  • Google Scholar

• 179

  Bongen E Vallania F Utz PJ Khatri P . KLRD1-expressing natural killer cells predict influenza susceptibility. Genome Med (2018) 10(1):45. doi: 10.1186/s13073-018-0554-1

  • CrossRef
  • Google Scholar

• 180

  Liu Y Zheng J Liu Y Wen L Huang L Xiang Z et al . Uncompromised NK cell activation is essential for virus-specific CTL activity during acute influenza virus infection. Cell Mol Immunol (2018) 15(9):827–37. doi: 10.1038/cmi.2017.10

  • CrossRef
  • Google Scholar

• 181

  Ishikawa H Tanaka K Kutsukake E Fukui T Sasaki H Hata A et al . IFN-gamma production downstream of NKT cell activation in mice infected with influenza virus enhances the cytolytic activities of both NK cells and viral antigen-specific CD8+ T cells. Virology (2010) 407(2):325–32. doi: 10.1016/j.virol.2010.08.030

  • CrossRef
  • Google Scholar

• 182

  Duan X Lu J Zhou K Wang J Wu J Fu Gao G et al . NK-cells are involved in thymic atrophy induced by influenza A virus infection. J Gen Virol (2015) 96(11):3223–35. doi: 10.1099/jgv.0.000276

  • CrossRef
  • Google Scholar

• 183

  Wagstaffe HR Pickering H Houghton J Mooney JP Wolf AS Prevatt N et al . Influenza vaccination primes human myeloid cell cytokine secretion and NK cell function. J Immunol (2019) 203(6):1609–18. doi: 10.4049/jimmunol.1801648

  • CrossRef
  • Google Scholar

• 184

  Long BR Michaelsson J Loo CP Ballan WM Vu BA Hecht FM et al . Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated against influenza virus. Clin Vaccine Immunol (2008) 15(1):120–30. doi: 10.1128/CVI.00357-07

  • CrossRef
  • Google Scholar

• 185

  Dou Y Fu B Sun R Li W Hu W Tian Z et al . Influenza vaccine induces intracellular immune memory of human NK cells. PloS One (2015) 10(3):e0121258. doi: 10.1371/journal.pone.0121258

  • CrossRef
  • Google Scholar

• 186

  Park J Fong Legaspi SL Schwartzman LM Gygli SM Sheng ZM Freeman AD et al . An inactivated multivalent influenza A virus vaccine is broadly protective in mice and ferrets. Sci Transl Med (2022) 14(653):eabo2167. doi: 10.1126/scitranslmed.abo2167

  • CrossRef
  • Google Scholar

• 187

  Naqvi AAT Fatima K Mohammad T Fatima U Singh IK Singh A et al . Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis (2020) 1866(10):165878. doi: 10.1016/j.bbadis.2020.165878

  • CrossRef
  • Google Scholar

• 188

  Lamers MM Haagmans BL . SARS-CoV-2 pathogenesis. Nat Rev Microbiol (2022) 20(5):270–84. doi: 10.1038/s41579-022-00713-0

  • CrossRef
  • Google Scholar

• 189

  Jiang Y Wei X Guan J Qin S Wang Z Lu H et al . COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential. Clin Immunol (2020) 218:108516. doi: 10.1016/j.clim.2020.108516

  • CrossRef
  • Google Scholar

• 190

  Li M Guo W Dong Y Wang X Dai D Liu X et al . Elevated exhaustion levels of NK and CD8(+) T cells as indicators for progression and prognosis of COVID-19 disease. Front Immunol (2020) 11:580237. doi: 10.3389/fimmu.2020.580237

  • CrossRef
  • Google Scholar

• 191

  Xu G Qi F Li H Yang Q Wang H Wang X et al . The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. Cell Discov (2020) 6:73. doi: 10.1038/s41421-020-00225-2

  • CrossRef
  • Google Scholar

• 192

  Maucourant C Filipovic I Ponzetta A Aleman S Cornillet M Hertwig L et al . Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol (2020) 5(50):eabd6832. doi: 10.1126/sciimmunol.abd6832

  • CrossRef
  • Google Scholar

• 193

  Wilk AJ Rustagi A Zhao NQ Roque J Martínez-Colón GJ McKechnie JL et al . A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med (2020) 26(7):1070–6. doi: 10.1038/s41591-020-0944-y

  • CrossRef
  • Google Scholar

• 194

  Witkowski M Tizian C Ferreira-Gomes M Niemeyer D Jones TC Heinrich F et al . Untimely TGFbeta responses in COVID-19 limit antiviral functions of NK cells. Nature (2021) 600(7888):295–301. doi: 10.1038/s41586-021-04142-6

  • CrossRef
  • Google Scholar

• 195

  Galán M Vigón L Fuertes D Murciano-Antón MA Casado-Fernández G Domínguez-Mateos S et al . Persistent overactive cytotoxic immune response in a spanish cohort of individuals with long-COVID: identification of diagnostic biomarkers. Front Immunol (2022) 13:848886. doi: 10.3389/fimmu.2022.848886

  • CrossRef
  • Google Scholar

• 196

  Beckmann ND Comella PH Cheng E Lepow L Beckmann AG Tyler SR et al . Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. Nat Commun (2021) 12(1):4854. doi: 10.1038/s41467-021-24981-1

  • CrossRef
  • Google Scholar

• 197

  Huang L Shi Y Gong B Jiang L Zhang Z Liu X et al . Dynamic blood single-cell immune responses in patients with COVID-19. Signal Transduct Target Ther (2021) 6(1):110. doi: 10.1038/s41392-021-00526-2

  • CrossRef
  • Google Scholar

• 198

  Herrera L Martin-Inaraja M Santos S Ingles-Ferrandiz M Azkarate A Perez-Vaquero MA et al . Identifying SARS-CoV-2 ‘memory’ NK cells from COVID-19 convalescent donors for adoptive cell therapy. Immunology (2022) 165(2):234–49. doi: 10.1111/imm.13432

  • CrossRef
  • Google Scholar

• 199

  Malengier-Devlies B Filtjens J Ahmadzadeh K Boeckx B Vandenhaute J De Visscher A et al . Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates. Front Immunol (2022) 13:861251. doi: 10.3389/fimmu.2022.861251

  • CrossRef
  • Google Scholar

• 200

  Hoste L Roels L Naesens L Bosteels V Vanhee S Dupont S et al . TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C. J Exp Med (2022) 219(2):e20211381. doi: 10.1084/jem.20211381

  • CrossRef
  • Google Scholar

• 201

  Bozzano F Dentone C Perrone C Di Biagio A Fenoglio D Parodi A et al . Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. PloS Pathog (2021) 17(4):e1009448. doi: 10.1371/journal.ppat.1009448

  • CrossRef
  • Google Scholar

• 202

  Mazzoni A Salvati L Maggi L Capone M Vanni A Spinicci M et al . Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest (2020) 130(9):4694–703. doi: 10.1172/JCI138554

  • CrossRef
  • Google Scholar

• 203

  Varchetta S Mele D Oliviero B Mantovani S Ludovisi S Cerino A et al . Unique immunological profile in patients with COVID-19. Cell Mol Immunol (2021) 18(3):604–12. doi: 10.1038/s41423-020-00557-9

  • CrossRef
  • Google Scholar

• 204

  Hutanu A Manu D Gabor MR Vasiesiu AM Andrejkovits AV Dobreanu M . Dynamic evaluation of natural killer cells subpopulations in COVID-19 patients. Int J Mol Sci (2022) 23(19):11875. doi: 10.3390/ijms231911875

  • CrossRef
  • Google Scholar

• 205

  Yaqinuddin A Kashir J . Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents. Med Hypotheses (2020) 140:109777. doi: 10.1016/j.mehy.2020.109777

  • CrossRef
  • Google Scholar

• 206

  Casado JL Moraga E Vizcarra P Velasco H Martin-Hondarza A Haemmerle J et al . Expansion of CD56(dim)CD16(neg) NK cell subset and increased inhibitory KIRs in hospitalized COVID-19 patients. Viruses (2021) 14(1):46. doi: 10.3390/v14010046

  • CrossRef
  • Google Scholar

• 207

  Hsieh WC Lai EY Liu YT Wang YF Tzeng YS Cui L et al . NK cell receptor and ligand composition influences the clearance of SARS-CoV-2. J Clin Invest (2021) 131(21):e146408. doi: 10.1172/JCI146408

  • CrossRef
  • Google Scholar

• 208

  Leem G Cheon S Lee H Choi SJ Jeong S Kim ES et al . Abnormality in the NK-cell population is prolonged in severe COVID-19 patients. J Allergy Clin Immunol (2021) 148(4):996–1006 e18. doi: 10.1016/j.jaci.2021.07.022

  • CrossRef
  • Google Scholar

• 209

  Wilk AJ Lee MJ Wei B Parks B Pi R Martinez-Colon GJ et al . Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. J Exp Med (2021) 218(8):e20210582. doi: 10.1101/2020.12.18.423363

  • CrossRef
  • Google Scholar

• 210

  Vigón L García-Pérez J Rodríguez-Mora S Torres M Mateos E Castillo de la Osa M et al . Impaired antibody-dependent cellular cytotoxicity in a spanish cohort of patients with COVID-19 admitted to the ICU. Front Immunol (2021) 12:742631. doi: 10.3389/fimmu.2021.742631

  • CrossRef
  • Google Scholar

• 211

  Fionda C Ruggeri S Sciume G Laffranchi M Quinti I Milito C et al . Age-dependent NK cell dysfunctions in severe COVID-19 patients. Front Immunol (2022) 13:1039120. doi: 10.3389/fimmu.2022.1039120

  • CrossRef
  • Google Scholar

• 212

  Huang CY Chung CL Hu TH Chen JJ Liu PF Chen CL . Recent progress in TGF-β inhibitors for cancer therapy. BioMed Pharmacother (2021) 134:111046. doi: 10.1016/j.biopha.2020.111046

  • CrossRef
  • Google Scholar

• 213

  Wang H Chen M Sang X You X Wang Y Paterson IC et al . Development of small molecule inhibitors targeting TGF-β ligand and receptor: Structures, mechanism, preclinical studies and clinical usage. Eur J Med Chem (2020) 191:112154. doi: 10.1016/j.ejmech.2020.112154

  • CrossRef
  • Google Scholar

• 214

  Chinnapaiyan S Dutta RK Nair M Chand HS Rahman I Unwalla HJ . TGF-beta1 increases viral burden and promotes HIV-1 latency in primary differentiated human bronchial epithelial cells. Sci Rep (2019) 9(1):12552. doi: 10.1038/s41598-019-49056-6

  • CrossRef
  • Google Scholar

• 215

  Kaczmarek Michaels K Natarajan M Euler Z Alter G Viglianti G Henderson AJ . Blimp-1, an intrinsic factor that represses HIV-1 proviral transcription in memory CD4+ T cells. J Immunol (2015) 194(7):3267–74. doi: 10.4049/jimmunol.1402581

  • CrossRef
  • Google Scholar

• 216

  Samer S Thomas Y Arainga M Carter C Shirreff LM Arif MS et al . Blockade of TGF-beta signaling reactivates HIV-1/SIV reservoirs and immune responses in vivo. JCI Insight (2022) 7(21):e162290. doi: 10.1172/jci.insight.162290

  • CrossRef
  • Google Scholar

• 217

  Barros-Martins J Forster R Bosnjak B . NK cell dysfunction in severe COVID-19: TGF-beta-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity. Signal Transduct Target Ther (2022) 7(1):32. doi: 10.1038/s41392-022-00892-5

  • CrossRef
  • Google Scholar

• 218

  Viel S Marcais A Guimaraes FS Loftus R Rabilloud J Grau M et al . TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal (2016) 9(415):ra19. doi: 10.1126/scisignal.aad1884

  • CrossRef
  • Google Scholar

• 219

  Khan M Arooj S Wang H . NK cell-based immune checkpoint inhibition. Front Immunol (2020) 11:167. doi: 10.3389/fimmu.2020.00167

  • CrossRef
  • Google Scholar

• 220

  Andre P Denis C Soulas C Bourbon-Caillet C Lopez J Arnoux T et al . Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell (2018) 175(7):1731–43 e13. doi: 10.1016/j.cell.2018.10.014

  • CrossRef
  • Google Scholar

• 221

  Ducoin K Oger R Bilonda Mutala L Deleine C Jouand N Desfrancois J et al . Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. Oncoimmunology (2022) 11(1):2046931. doi: 10.1080/2162402X.2022.2046931

  • CrossRef
  • Google Scholar

• 222

  Ruggeri L Urbani E Andre P Mancusi A Tosti A Topini F et al . Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica (2016) 101(5):626–33. doi: 10.3324/haematol.2015.135301

  • CrossRef
  • Google Scholar

• 223

  Li F Wei H Wei H Gao Y Xu L Yin W et al . Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. Gastroenterology (2013) 144(2):392–40. doi: 10.1053/j.gastro.2012.10.039

  • CrossRef
  • Google Scholar

• 224

  Zheng M Gao Y Wang G Song G Liu S Sun D et al . Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol (2020) 17(5):533–5. doi: 10.1038/s41423-020-0402-2

  • CrossRef
  • Google Scholar

• 225

  Sarwar Z Ahmad T Kakar S . Potential approaches to combat COVID-19: a mini-review. Mol Biol Rep (2020) 47(12):9939–49. doi: 10.1007/s11033-020-05988-1

  • CrossRef
  • Google Scholar

• 226

  Benson DM Hofmeister CC Padmanabhan S Suvannasankha A Jagannath S Abonour R et al . A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood (2012) 120(22):4324–33. doi: 10.1182/blood-2012-06-438028

  • CrossRef
  • Google Scholar

• 227

  Carlsten M Korde N Kotecha R Reger R Bor S Kazandjian D et al . Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma. Clin Cancer Res (2016) 22(21):5211–22. doi: 10.1158/1078-0432.CCR-16-1108

  • CrossRef
  • Google Scholar

• 228

  Vey N Goncalves A Karlin L Lebouvier-Sadot S Broussais F Marie D et al . A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid Malignancies (SOL). J Clin Oncol (2015) 33(15_suppl):3065. doi: 10.1200/jco.2015.33.15_suppl.3065

  • CrossRef
  • Google Scholar

• 229

  Benson DM Bakan CE Zhang S Collins SM Liang J Srivastava S et al . IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood (2011) 118(24):6387–91. doi: 10.1182/blood-2011-06-360255

  • CrossRef
  • Google Scholar

• 230

  Benson DM Cohen AD Jagannath S Munshi NC Spitzer G Hofmeister CC et al . A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin Cancer Res (2015) 21(18):4055–61. doi: 10.1158/1078-0432.CCR-15-0304

  • CrossRef
  • Google Scholar

• 231

  Vey N Bourhis J-H Dombret H Bordessoule D Prébet T Charbonnier A et al . A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1-7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML): clinical and immunological effects of a single dose followed by repeated dosing. Blood (2009) 114(22):632–. doi: 10.1182/blood.V114.22.632.632

  • CrossRef
  • Google Scholar

• 232

  Bagot M Porcu P Marie-Cardine A Battistella M William BM Vermeer M et al . IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol (2019) 20(8):1160–70. doi: 10.1016/S1470-2045(19)30320-1

  • CrossRef
  • Google Scholar

• 233

  Liu J Chen Z Li Y Zhao W Wu J Zhang Z . PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol (2021) 12:731798. doi: 10.3389/fphar.2021.731798

  • CrossRef
  • Google Scholar

• 234

  Alsaab HO Sau S Alzhrani R Tatiparti K Bhise K Kashaw SK et al . PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol (2017) 8:561. doi: 10.3389/fphar.2017.00561

  • CrossRef
  • Google Scholar

• 235

  Benson DM Bakan CE Mishra A Hofmeister CC Efebera Y Becknell B et al . The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 116(13):2286–94. doi: 10.1182/blood-2010-02-271874

  • CrossRef
  • Google Scholar

• 236

  MacFarlane AW Jillab M Plimack ER Hudes GR Uzzo RG Litwin S et al . PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res (2014) 2(4):320–31. doi: 10.1158/2326-6066.CIR-13-0133

  • CrossRef
  • Google Scholar

• 237

  Beldi-Ferchiou A Lambert M Dogniaux S Vély F Vivier E Olive D et al . PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget (2016) 7(45):72961–77. doi: 10.18632/oncotarget.12150

  • CrossRef
  • Google Scholar

• 238

  Ai L Chen J Yan H He Q Luo P Xu Z et al . Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy. Drug Des Devel Ther (2020) 14:3625–49. doi: 10.2147/DDDT.S267433

  • CrossRef
  • Google Scholar

• 239

  Norris S Coleman A Kuri-Cervantes L Bower M Nelson M Goodier MR . PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection. Viral Immunol (2012) 25(4):329–32. doi: 10.1089/vim.2011.0096

  • CrossRef
  • Google Scholar

• 240

  Bertoletti A Gehring AJ . The immune response during hepatitis B virus infection. J Gen Virol (2006) 87(6):1439–49. doi: 10.1099/vir.0.81920-0

  • CrossRef
  • Google Scholar

• 241

  Salem ML El-Badawy A . Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol (2015) 7(23):2449–58. doi: 10.4254/wjh.v7.i23.2449

  • CrossRef
  • Google Scholar

• 242

  Pauken KE Godec J Odorizzi PM Brown KE Yates KB Ngiow SF et al . The PD-1 pathway regulates development and function of memory CD8. Cell Rep (2020) 31(13):107827. doi: 10.1016/j.celrep.2020.107827

  • CrossRef
  • Google Scholar

• 243

  Aghbash PS Eslami N Shamekh A Entezari-Maleki T Baghi HB . SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis. Life Sci (2021) 270:119124. doi: 10.1016/j.lfs.2021.119124

  • CrossRef
  • Google Scholar

• 244

  McNally B Ye F Willette M Flaño E . Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection. J Virol (2013) 87(23):12916–24. doi: 10.1128/JVI.02423-13

  • CrossRef
  • Google Scholar

• 245

  Velu V Titanji K Zhu B Husain S Pladevega A Lai L et al . Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2009) 458(7235):206–10. doi: 10.1038/nature07662

  • CrossRef
  • Google Scholar

• 246

  Palmer BE Neff CP Lecureux J Ehler A Dsouza M Remling-Mulder L et al . In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol (2013) 190(1):211–9. doi: 10.4049/jimmunol.1201108

  • CrossRef
  • Google Scholar

• 247

  Fisicaro P Valdatta C Massari M Loggi E Biasini E Sacchelli L et al . Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology (2010) 138(2):682–93, 93.e1-4. doi: 10.1053/j.gastro.2009.09.052

  • CrossRef
  • Google Scholar

• 248

  Moebius J Guha R Peterson M Abdi K Skinner J Li S et al . PD-1 expression on NK cells in malaria-exposed individuals is associated with diminished natural cytotoxicity and enhanced antibody-dependent cellular cytotoxicity. Infect Immun (2020) 88(3):e00711–19. doi: 10.1128/IAI.00711-19

  • CrossRef
  • Google Scholar

• 249

  Rao M Valentini D Dodoo E Zumla A Maeurer M . Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis (2017) 56:221–8. doi: 10.1016/j.ijid.2017.01.028

  • CrossRef
  • Google Scholar

• 250

  Davis ZB Felices M Verneris MR Miller JS . Natural killer cell adoptive transfer therapy: exploiting the first line of defense against cancer. Cancer J (2015) 21(6):486–91. doi: 10.1097/PPO.0000000000000156

  • CrossRef
  • Google Scholar

• 251

  Iliopoulou EG Kountourakis P Karamouzis MV Doufexis D Ardavanis A Baxevanis CN et al . A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother (2010) 59(12):1781–9. doi: 10.1007/s00262-010-0904-3

  • CrossRef
  • Google Scholar

• 252

  Geller MA Cooley S Judson PL Ghebre R Carson LF Argenta PA et al . A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy (2011) 13(1):98–107. doi: 10.3109/14653249.2010.515582

  • CrossRef
  • Google Scholar

• 253

  Arai S Meagher R Swearingen M Myint H Rich E Martinson J et al . Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy (2008) 10(6):625–32. doi: 10.1080/14653240802301872

  • CrossRef
  • Google Scholar

• 254

  Woan KV Kim H Bjordahl R Davis ZB Gaidarova S Goulding J et al . Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell (2021) 28(12):2062–75 e5. doi: 10.1016/j.stem.2021.08.013

  • CrossRef
  • Google Scholar

• 255

  Ni Z Knorr DA Bendzick L Allred J Kaufman DS . Expression of chimeric receptor CD4zeta by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells (2014) 32(4):1021–31. doi: 10.1002/stem.1611

  • CrossRef
  • Google Scholar

• 256

  Kim JT Zhang TH Carmona C Lee B Seet CS Kostelny M et al . Latency reversal plus natural killer cells diminish HIV reservoir in vivo. Nat Commun (2022) 13(1):121. doi: 10.1038/s41467-021-27647-0

  • CrossRef
  • Google Scholar

• 257

  Huntington ND Legrand N Alves NL Jaron B Weijer K Plet A et al . IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med (2009) 206(1):25–34. doi: 10.1084/jem.20082013

  • CrossRef
  • Google Scholar

• 258

  Conlon KC Lugli E Welles HC Rosenberg SA Fojo AT Morris JC et al . Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol (2015) 33(1):74–82. doi: 10.1200/JCO.2014.57.3329

  • CrossRef
  • Google Scholar

• 259

  Romee R Rosario M Berrien-Elliott MM Wagner JA Jewell BA Schappe T et al . Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med (2016) 8(357):357ra123. doi: 10.1126/scitranslmed.aaf2341

  • CrossRef
  • Google Scholar

• 260

  Wagstaffe HR Nielsen CM Riley EM Goodier MR . IL-15 promotes polyfunctional NK cell responses to influenza by boosting IL-12 production. J Immunol (2018) 200(8):2738–47. doi: 10.4049/jimmunol.1701614

  • CrossRef
  • Google Scholar

• 261

  Garrido C Abad-Fernandez M Tuyishime M Pollara JJ Ferrari G Soriano-Sarabia N et al . Interleukin-15-stimulated natural killer cells clear HIV-1-infected cells following latency reversal. J Virol (2018) 92(12):262. doi: 10.1128/JVI.00235-18

  • CrossRef
  • Google Scholar

• 262

  Terrén I Orrantia A Astarloa-Pando G Amarilla-Irusta A Zenarruzabeitia O Borrego F . Cytokine-induced memory-like NK cells: from the basics to clinical applications. Front Immunol (2022) 13:884648. doi: 10.3389/fimmu.2022.884648

  • CrossRef
  • Google Scholar

• 263

  Romee R Schneider SE Leong JW Chase JM Keppel CR Sullivan RP et al . Cytokine activation induces human memory-like NK cells. Blood (2012) 120(24):4751–60. doi: 10.1182/blood-2012-04-419283

  • CrossRef
  • Google Scholar

• 264

  Berrien-Elliott MM Wagner JA Fehniger TA . Human cytokine-induced memory-like natural killer cells. J Innate Immun (2015) 7(6):563–71. doi: 10.1159/000382019

  • CrossRef
  • Google Scholar

• 265

  Shapiro RM Birch GC Hu G Vergara Cadavid J Nikiforow S Baginska J et al . Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest (2022) 132(11):e154334. doi: 10.1172/JCI154334

  • CrossRef
  • Google Scholar

• 266

  Bednarski JJ Zimmerman C Berrien-Elliott MM Foltz JA Becker-Hapak M Neal CC et al . Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood (2022) 139(11):1670–83. doi: 10.1182/blood.2021013972

  • CrossRef
  • Google Scholar

• 267

  Berrien-Elliott MM Foltz JA Russler-Germain DA Neal CC Tran J Gang M et al . Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Sci Transl Med (2022) 14(633):eabm1375. doi: 10.1126/scitranslmed.abm1375

  • CrossRef
  • Google Scholar

• 268

  Ellis-Connell AL Balgeman AJ Zarbock KR Barry G Weiler A Egan JO et al . ALT-803 transiently reduces simian immunodeficiency virus replication in the absence of antiretroviral treatment. J Virol (2018) 92(3):e01748–17. doi: 10.1128/JVI.01748-17

  • CrossRef
  • Google Scholar

• 269

  Webb GM Molden J Busman-Sahay K Abdulhaqq S Wu HL Weber WC et al . The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PloS Pathog (2020) 16(3):e1008339. doi: 10.1371/journal.ppat.1008339

  • CrossRef
  • Google Scholar

• 270

  Miller JS Davis ZB Helgeson E Reilly C Thorkelson A Anderson J et al . Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nat Med (2022) 28(2):392–400. doi: 10.1038/s41591-021-01651-9

  • CrossRef
  • Google Scholar

• 271

  Lynch RM Boritz E Coates EE DeZure A Madden P Costner P et al . Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med (2015) 7(319):319ra206. doi: 10.1126/scitranslmed.aad5752

  • CrossRef
  • Google Scholar

• 272

  Caskey M . Broadly neutralizing antibodies for the treatment and prevention of HIV infection. Curr Opin HIV AIDS (2020) 15(1):49–55. doi: 10.1097/COH.0000000000000600

  • CrossRef
  • Google Scholar

• 273

  Haynes BF Wiehe K Borrow P Saunders KO Korber B Wagh K et al . Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat Rev Immunol (2023) 23(3):142–58. doi: 10.1038/s41577-022-00753-w

  • CrossRef
  • Google Scholar

• 274

  Rerks-Ngarm S Pitisuttithum P Nitayaphan S Kaewkungwal J Chiu J Paris R et al . Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 361(23):2209–20. doi: 10.1056/NEJMoa0908492

  • CrossRef
  • Google Scholar

• 275

  Haynes BF Gilbert PB McElrath MJ Zolla-Pazner S Tomaras GD Alam SM et al . Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 366(14):1275–86. doi: 10.1056/NEJMoa1113425

  • CrossRef
  • Google Scholar

• 276

  Karasavvas N Billings E Rao M Williams C Zolla-Pazner S Bailer RT et al . The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 28(11):1444–57. doi: 10.1089/aid.2012.0103

  • CrossRef
  • Google Scholar

• 277

  Yates NL Liao HX Fong Y deCamp A Vandergrift NA Williams WT et al . Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 6(228):228ra39. doi: 10.1126/scitranslmed.3007730

  • CrossRef
  • Google Scholar

• 278

  Bonsignori M Pollara J Moody MA Alpert MD Chen X Hwang KK et al . Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 86(21):11521–32. doi: 10.1128/JVI.01023-12

  • CrossRef
  • Google Scholar

• 279

  Li SS Gilbert PB Tomaras GD Kijak G Ferrari G Thomas R et al . FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest (2014) 124(9):3879–90. doi: 10.1172/JCI75539

  • CrossRef
  • Google Scholar

• 280

  Alpert MD Harvey JD Lauer WA Reeves RK Piatak M Carville A et al . ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PloS Pathog (2012) 8(8):e1002890. doi: 10.1371/journal.ppat.1002890

  • CrossRef
  • Google Scholar

• 281

  Forthal DN Gilbert PB Landucci G Phan T . Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol (2007) 178(10):6596–603. doi: 10.4049/jimmunol.178.10.6596

  • CrossRef
  • Google Scholar

• 282

  Nag P Kim J Sapiega V Landay AL Bremer JW Mestecky J et al . Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis (2004) 190(11):1970–8. doi: 10.1086/425582

  • CrossRef
  • Google Scholar

• 283

  Wren LH Chung AW Isitman G Kelleher AD Parsons MS Amin J et al . Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology (2013) 138(2):116–23. doi: 10.1111/imm.12016

  • CrossRef
  • Google Scholar

• 284

  Lu CL Murakowski DK Bournazos S Schoofs T Sarkar D Halper-Stromberg A et al . Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science (2016) 352(6288):1001–4. doi: 10.1126/science.aaf1279

  • CrossRef
  • Google Scholar

• 285

  Wei X Decker JM Wang S Hui H Kappes JC Wu X et al . Antibody neutralization and escape by HIV-1. Nature (2003) 422(6929):307–12. doi: 10.1038/nature01470

  • CrossRef
  • Google Scholar

• 286

  Meijers M Vanshylla K Gruell H Klein F Lässig M . Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody. Proc Natl Acad Sci USA (2021) 118(30):e2104651118. doi: 10.1073/pnas.2104651118

  • CrossRef
  • Google Scholar

• 287

  Dingens AS Arenz D Weight H Overbaugh J Bloom JD . An antigenic atlas of HIV-1 escape from broadly neutralizing antibodies distinguishes functional and structural epitopes. Immunity (2019) 50(2):520–32.e3. doi: 10.1016/j.immuni.2018.12.017

  • CrossRef
  • Google Scholar

• 288

  Isitman G Stratov I Kent SJ . Antibody-dependent cellular cytotoxicity and NK cell-driven immune escape in HIV infection: implications for HIV vaccine development. Adv Virol (2012) 2012:637208. doi: 10.1155/2012/637208

  • CrossRef
  • Google Scholar

• 289

  Tudor D Yu H Maupetit J Drillet AS Bouceba T Schwartz-Cornil I et al . Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci USA (2012) 109(31):12680–5. doi: 10.1073/pnas.1200024109

  • CrossRef
  • Google Scholar

• 290

  Richardson SI Lambson BE Crowley AR Bashirova A Scheepers C Garrett N et al . IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PloS Pathog (2019) 15(12):e1008064. doi: 10.1371/journal.ppat.1008064

  • CrossRef
  • Google Scholar

• 291

  de Taeye SW Bentlage AEH Mebius MM Meesters JI Lissenberg-Thunnissen S Falck D et al . FcγR binding and ADCC activity of human IgG allotypes. Front Immunol (2020) 11:740. doi: 10.3389/fimmu.2020.00740

  • CrossRef
  • Google Scholar

• 292

  Demaria O Gauthier L Debroas G Vivier E . Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments. Eur J Immunol (2021) 51(8):1934–42. doi: 10.1002/eji.202048953

  • CrossRef
  • Google Scholar

• 293

  Pinto S Pahl J Schottelius A Carter PJ Koch J . Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. Trends Immunol (2022) 43(11):932–46. doi: 10.1016/j.it.2022.09.007

  • CrossRef
  • Google Scholar

• 294

  Au KM Park SI Wang AZ . Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Sci Adv (2020) 6(27):eaba8564. doi: 10.1126/sciadv.aba8564

  • CrossRef
  • Google Scholar

• 295

  Mei Y Xiang B Yang J . Novel strategies for redirecting NK cells in cancer immunotherapy. J Nutr Oncol (2017) 2(2):66–72. doi: 10.34175/jno201702003

  • CrossRef
  • Google Scholar

• 296

  Ma J Mo Y Tang M Shen J Qi Y Zhao W et al . Bispecific antibodies: from research to clinical application. Front Immunol (2021) 12:626616. doi: 10.3389/fimmu.2021.626616

  • CrossRef
  • Google Scholar

• 297

  Li H Er Saw P Song E . Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol (2020) 17(5):451–61. doi: 10.1038/s41423-020-0417-8

  • CrossRef
  • Google Scholar

• 298

  Vallera DA Felices M McElmurry R McCullar V Zhou X Schmohl JU et al . IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ Targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res (2016) 22(14):3440–50. doi: 10.1158/1078-0432.CCR-15-2710

  • CrossRef
  • Google Scholar

• 299

  Huehls AM Coupet TA Sentman CL . Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol (2015) 93(3):290–6. doi: 10.1038/icb.2014.93

  • CrossRef
  • Google Scholar

• 300

  Sung JA Pickeral J Liu L Stanfield-Oakley SA Lam CY Garrido C et al . Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J Clin Invest (2015) 125(11):4077–90. doi: 10.1172/JCI82314

  • CrossRef
  • Google Scholar

• 301

  Moore PA Zhang W Rainey GJ Burke S Li H Huang L et al . Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood (2011) 117(17):4542–51. doi: 10.1182/blood-2010-09-306449

  • CrossRef
  • Google Scholar

• 302

  Phung SK Miller JS Felices M . Bi-specific and tri-specific NK cell engagers: the new avenue of targeted NK cell immunotherapy. Mol Diagn Ther (2021) 25(5):577–92. doi: 10.1007/s40291-021-00550-6

  • CrossRef
  • Google Scholar

• 303

  Oboshi W Watanabe T Matsuyama Y Kobara A Yukimasa N Ueno I et al . The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects. Hum Immunol (2016) 77(2):165–71. doi: 10.1016/j.humimm.2015.11.001

  • CrossRef
  • Google Scholar

• 304

  Coënon L Villalba M . From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement. Front Immunol (2022) 13:913215. doi: 10.3389/fimmu.2022.913215

  • CrossRef
  • Google Scholar

• 305

  Talathi SP Shaikh NN Pandey SS Saxena VA Mamulwar MS Thakar MR . FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV. BMC Infect Dis (2019) 19(1):1053. doi: 10.1186/s12879-019-4674-z

  • CrossRef
  • Google Scholar

• 306

  Felices M Lenvik TR Davis ZB Miller JS Vallera DA . Generation of biKEs and TriKEs to improve NK cell-mediated targeting of tumor cells. Methods Mol Biol (2016) 1441:333–46. doi: 10.1007/978-1-4939-3684-7_28

  • CrossRef
  • Google Scholar

• 307

  Tay SS Carol H Biro M . TriKEs and BiKEs join CARs on the cancer immunotherapy highway. Hum Vaccin Immunother (2016) 12(11):2790–6. doi: 10.1080/21645515.2016.1198455

  • CrossRef
  • Google Scholar

• 308

  Davis ZB Vallera DA Miller JS Felices M . Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol (2017) 31:64–75. doi: 10.1016/j.smim.2017.07.011

  • CrossRef
  • Google Scholar

• 309

  Davis ZB Lenvik T Hansen L Felices M Cooley S Vallera D et al . A novel HIV envelope bi-specific killer engager enhances natural killer cell mediated ADCC responses against HIV-infected cells. Blood (2016) 128(22):2517–. doi: 10.1182/blood.V128.22.2517.2517

  • CrossRef
  • Google Scholar

• 310

  Wilen CB Tilton JC Doms RW . HIV: cell binding and entry. Cold Spring Harb Perspect Med (2012) 2(8):a006866. doi: 10.1101/cshperspect.a006866

  • CrossRef
  • Google Scholar

• 311

  Chen W Feng Y Gong R Zhu Z Wang Y Zhao Q et al . Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J Virol (2011) 85(18):9395–405. doi: 10.1128/JVI.05119-11

  • CrossRef
  • Google Scholar

• 312

  Sakihama T Smolyar A Reinherz EL . Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. Proc Natl Acad Sci USA (1995) 92(14):6444–8. doi: 10.1073/pnas.92.14.6444

  • CrossRef
  • Google Scholar

• 313

  Lamarre D Capon DJ Karp DR Gregory T Long EO Sékaly RP . Class II MHC molecules and the HIV gp 120 envelope protein interact with functionally distinct regions of the CD4 molecule. EMBO J (1989) 8(11):3271–7. doi: 10.1002/j.1460-2075.1989.tb08487.x

  • CrossRef
  • Google Scholar

• 314

  Chen W Feng Y Prabakaran P Ying T Wang Y Sun J et al . Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol (2014) 88(2):1125–39. doi: 10.1128/JVI.02566-13

  • CrossRef
  • Google Scholar

• 315

  Li W Wu Y Kong D Yang H Wang Y Shao J et al . One-domain CD4 fused to human anti-CD16 antibody domain mediates effective killing of HIV-1-infected cells. Sci Rep (2017) 7(1):9130. doi: 10.1038/s41598-017-07966-3

  • CrossRef
  • Google Scholar

• 316

  Li H Song W Li Z Zhang M . Preclinical and clinical studies of CAR-NK-cell therapies for Malignancies. Front Immunol (2022) 13:992232. doi: 10.3389/fimmu.2022.992232

  • CrossRef
  • Google Scholar

• 317

  Lu T Ma R Dong W Teng KY Kollath DS Li Z et al . Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. Nat Commun (2022) 13(1):2576. doi: 10.1038/s41467-022-30216-8

  • CrossRef
  • Google Scholar

• 318

  Mazarzaei A Vafaei M Ghasemian A Mirforughi SA Rajabi Vardanjani H Alwan NAS . Memory and CAR-NK cell-based novel approaches for HIV vaccination and eradication. J Cell Physiol (2019) 234(9):14812–7. doi: 10.1002/jcp.28280

  • CrossRef
  • Google Scholar

• 319

  Lim RM Rong L Zhen A Xie J . A universal CAR-NK cell targeting various epitopes of HIV-1 gp160. ACS Chem Biol (2020) 15(8):2299–310. doi: 10.1021/acschembio.0c00537

  • CrossRef
  • Google Scholar